Contents
- What this report adds
- About this survey
- I. R&D investment
- I-1. H1 2026 R&D spend — sector × size
- I-2. Year-on-year change
- I-3. Trend
- I-4. The twenty largest spenders
- I-5. Largest increases and decreases
- I-6. How R&D is accounted for, and what it buys
- II. Profitability and funding
- II-1. Revenue, operating profit and R&D intensity
- II-2. Distribution of R&D intensity
- II-3. R&D at loss-making companies
- II-4. Highest R&D intensity
- II-5. Domestic and export sales
- II-6. Capital raising — equity and bonds
- II-7. How loss-makers keep funding research
- III. People
- III-1. Headcount and change
- III-2. R&D per employee
- IV. Investment and output
- IV-1. Two years of spend and disclosed output, by sector
- IV-2. Concentration
- IV-3. Approvals and trials per KRW 10bn
- IV-4. Publications per KRW 10bn
- IV-5. Companies with no disclosed output
- IV-6. Pipeline by phase
- IV-7. Licensing — when research earns money
- V. The largest spenders up close
- V-1. Celltrion, Inc.
- V-2. YUHAN CORPORATION
- V-3. DAEWOONG PHARMA
- V-4. Hanmi Pharm. Co., Ltd.
- V-5. SAMSUNG EPIS HOLDINGS Co., Ltd.
- V-6. GC Biopharma Corp.
- V-7. Chong Kun Dang Pharmaceutical Corp.
- V-8. SK biopharmaceuticals Co., Ltd.
- V-9. LigaChem Biosciences Inc.
- V-10. SAMSUNG BIOLOGICS CO.,LTD.
- What the numbers say
- Method and limits
- Appendix. Company table
Medical AI Alliance (2026), "R&D Investment and Output, Korea's Listed Healthcare Sector — H1 2026", MAA Report, https://medicalaialliance.org/en/reports/rnd-invest-2026h1 (full edition 2026-10-07)
© 2026 Medical AI Alliance. This report and its company data are licensed under the Creative Commons Attribution 4.0 International licence (CC BY 4.0, https://creativecommons.org/licenses/by/4.0/): free to share and adapt, including commercially, with attribution to Medical AI Alliance (MAA) and an indication of any changes.
Key findings
- 252 listed healthcare companies spent KRW 3.08tn on R&D in H1 2026, +15.3% year on year on a like-for-like basis.
- A few companies drove the rise. The ten largest increases made 84% of the net increase, while 89 companies cut spending.
- 32.5% of R&D is spent by loss-making companies. 76 of the 114 loss-makers decided equity or bond issues in 2024–2025, worth 1.4x their R&D over the same years.
- Biotech spends 30% of revenue on R&D at a -15% operating margin; pharma & CDMO 8% and 15%.
- 17 companies disclosed 25 out-licensing deals. The 15 with a KRW value total KRW 15.26tn; upfronts: KRW 522.9bn (17 deals).
- 34 companies run phase 3 trials. 2024–2025: 43 Korean and 52 global phase 3 starts; 224 bioequivalence studies counted separately.
- Companies with reconciled accounting capitalise 15.8% of R&D. Exports are 27.7% of sales on the sales-table basis (38.5% including overseas subsidiaries' sales).
- Over 2024–2025, 260 companies spent KRW 11.14tn on R&D; the same period produced 1,874 approvals, 284 Korean trial authorisations and 1,081 papers. Among the Korean reports we reviewed, the first to join spend and output company by company.
At a glance
What this report adds
- It joins money to output, company by company. Two years of R&D at 260 companies sit next to the same companies' approvals, trials by phase, papers, patents and licensing deals. The Korean reports we reviewed count spending only.
- It shows where the money comes from. R&D at 114 loss-making companies is set against 353 equity and bond issue decisions on the same company axis.
- It names companies and publishes the full data. An appendix and CSV for all 252 companies let anyone recompute the figures.
- It shows its checks. Ratios are recomputed with the filing form's formula; the 11 companies whose self-reported ratio differs, and every correction, are disclosed. Key figures are cross-checked through two independent paths.
- It is fast and regular. August half-year filings are analysed in October; medical AI is tracked as its own sector.
- It counts licensing and pipelines from the filings. 34 companies with phase 3 trials and 25 out-licensing deals, each read from the source filing and checked against a verbatim quote.
About this survey
Coverage — 252 Korean listed healthcare, biotech and medical-device companies whose H1 2026 R&D spend passed our cross-check. 19 companies whose main business is not healthcare and 10 parents that consolidate listed subsidiaries (nine holding companies and SK Chemicals) are excluded. It covers every index company whose R&D passed our cross-check; those that did not are reported in the method section.
Reference date — 30 June 2026. Income and R&D are January–June totals; headcount is at period end. Prior-year figures are those restated in the 2026 filings.
Breakdowns — five MAA index sectors, and company size as each company declares it in its periodic filing (large 12 · mid-sized 88 · SME 152). Definitions are in the method section.
Interests — MAA member companies are among those covered; membership has no bearing on any figure or ranking. Every number is computed from public filings and databases under the same rules.
Prepared by the Medical AI Alliance (MAA), computed 2026-10-07. The table shows how many companies each item covers; counts differ because only cross-checked values are used.
| Item | Source | Companies (n) |
|---|---|---|
| R&D spend, change, trend | R&D expense table in half-year and annual filings | 252 |
| R&D accounting (expensed / capitalised) | Accounting lines of the same table | 188 |
| R&D by nature | Nature lines of the same table | 134 |
| Revenue, operating profit | DART financial API (KRW filers) | 244 |
| Domestic vs export sales | Sales table, else regional note | 172 |
| Employees | DART employee status (parent) | 242 |
| Company size | SME / mid-sized status as self-declared | 252 |
| Approvals, trials, papers, patents (2 years) | MFDS, FDA, ClinicalTrials.gov, PubMed, KIPRIS | 260 |
I. R&D investment
How much, where it grew, how it was accounted for
- Pharma & CDMO (98 companies) spent 55% of R&D
- Up 15.3% across 204 comparable companies, yet 89 cut spending
- The ten largest increases made up 84% of the net rise
I-1. H1 2026 R&D spend — sector × size
- H1 2026 R&D spend across 252 companies was KRW 3.08tn.
- By sector, Pharma & CDMO (98 companies) accounted for 55.3%.
- By size, mid-sized companies (88) spent the most at 51.4%; the 12 large companies spent 25.7%.
| Sector \ size (KRW bn) | Large | Mid-sized | SME | All |
|---|---|---|---|---|
| Pharma & CDMO | 518.3 (8) | 1,106.2 (52) | 80.1 (38) | 1,704.5 (98) |
| Biotech & drug discovery | 275.5 (4) | 232.6 (10) | 477.7 (54) | 985.8 (68) |
| Medical devices | — | 240.0 (24) | 95.5 (43) | 335.5 (67) |
| Medical AI | — | — | 46.3 (12) | 46.3 (12) |
| Healthcare infrastructure | — | — (2) | 5.3 (5) | 11.9 (7) |
| All | 793.8 (12) | 1,585.5 (88) | 704.8 (152) | 3,084.1 (252) |
Company counts in brackets. Cells with fewer than three companies are shown as "—".
I-2. Year-on-year change
- Among the 204 companies comparable year on year, R&D spend rose 15.3%: 115 increased and 89 decreased.
- Growth was fastest in Biotech & drug discovery (+26.4%) and slowest in Medical AI (+0.7%), among sectors with ten or more companies.
- Aggregate growth follows the largest spenders; read it alongside the count of companies that rose and fell.
| Sector \ size | Large | Mid-sized | SME | All |
|---|---|---|---|---|
| Pharma & CDMO | +23.1% (6) | +8.6% (43) | +8.7% (34) | +11.6% (83) |
| Biotech & drug discovery | +29.4% (4) | +33.6% (9) | +20.8% (44) | +26.4% (57) |
| Medical devices | — | +12.5% (21) | -12.8% (26) | +6.0% (47) |
| Medical AI | — | — | +0.7% (10) | +0.7% (10) |
| Healthcare infrastructure | — | — (2) | -12.7% (5) | +3.1% (7) |
| All | +25.9% (10) | +12.4% (75) | +13.0% (119) | +15.3% (204) |
Growth is computed on the same companies' totals; brackets show companies compared. Companies whose consolidation scope changed (e.g. the Samsung Biologics demerger) are excluded.
I-3. Trend
- The same 203 companies with values in all five periods.
- Annual R&D went from KRW 4.32tn in 2023 to KRW 5.04tn in 2025 (+16.5%).
- Half-year on half-year: +15.3%.
| Sector (KRW bn) | FY2023 | FY2024 | FY2025 | H1 2025 | H1 2026 |
|---|---|---|---|---|---|
| Pharma & CDMO | 2,551.8 | 2,621.8 | 2,768.1 | 1,312.3 | 1,464.5 |
| Biotech & drug discovery | 1,207.5 | 1,308.7 | 1,600.7 | 725.1 | 916.4 |
| Medical devices | 477.4 | 543.6 | 553.8 | 263.4 | 279.1 |
| Medical AI | 58.2 | 74.9 | 91.4 | 40.5 | 40.8 |
| Healthcare infrastructure | 27.1 | 27.8 | 22.4 | 11.5 | 11.9 |
| All | 4,321.9 | 4,576.9 | 5,036.4 | 2,352.9 | 2,712.7 |
I-4. The twenty largest spenders
- The top twenty spent KRW 1.79tn, 58.2% of the total.
- Celltrion, Inc. leads with KRW 284.3bn.
- Ratios to revenue vary with stage: large-revenue companies spend more in absolute terms at lower ratios.
| Rank | Company | Sector | Size | H1 2026 (KRW bn) | YoY | % of revenue |
|---|---|---|---|---|---|---|
| 1 | Celltrion, Inc. | Pharma & CDMO | Large | 284.3 | +23.8% | 11.2% |
| 2 | LigaChem Biosciences Inc. | Biotech & drug discovery | Mid-sized | 137.1 | +77.4% | 331.1% |
| 3 | Hanmi Pharm. Co., Ltd. | Pharma & CDMO | Mid-sized | 125.5 | +18.2% | 14.6% |
| 4 | SK Bioscience Co.,Ltd | Biotech & drug discovery | Large | 122.4 | +80.0% | 37.7% |
| 5 | YUHAN CORPORATION | Pharma & CDMO | Mid-sized | 122.2 | +13.8% | 10.5% |
| 6 | DAEWOONG PHARMA | Pharma & CDMO | Mid-sized | 115.7 | +8.5% | 15.7% |
| 7 | Chong Kun Dang Pharmaceutical Corp. | Pharma & CDMO | Mid-sized | 113.5 | +36.6% | 12.3% |
| 8 | SAMSUNG EPIS HOLDINGS Co., Ltd. | Pharma & CDMO | Large | 106.0 | — | 12.5% |
| 9 | SK biopharmaceuticals Co., Ltd. | Biotech & drug discovery | Large | 97.3 | +19.2% | 20.5% |
| 10 | GC Biopharma Corp. | Pharma & CDMO | Mid-sized | 85.9 | +3.8% | 10.0% |
| 11 | SAMSUNG BIOLOGICS CO.,LTD. | Pharma & CDMO | Large | 81.9 | — | 3.2% |
| 12 | DONG-A ST CO.,LTD | Pharma & CDMO | Mid-sized | 55.2 | -8.5% | 12.9% |
| 13 | ABL Bio Inc. | Biotech & drug discovery | SME | 48.8 | -8.9% | 148.6% |
| 14 | Kolon TissueGene, Inc. | Biotech & drug discovery | Large | 48.0 | -11.4% | — |
| 15 | MEDIPOSTCO.,LTD. | Biotech & drug discovery | SME | 44.0 | +28.3% | 115.1% |
| 16 | JW PHARMACEUTICAL | Pharma & CDMO | Mid-sized | 43.1 | -11.5% | 10.2% |
| 17 | SD BIOSENSOR INC. | Medical devices | Mid-sized | 42.9 | +18.8% | 11.3% |
| 18 | HK inno.N Corporation | Pharma & CDMO | Mid-sized | 42.6 | +12.8% | 8.1% |
| 19 | Voronoi, Inc. | Biotech & drug discovery | SME | 41.7 | +95.4% | — |
| 20 | JEIL PHARMACEUTICAL CO.,LTD | Pharma & CDMO | Mid-sized | 35.9 | +68.4% | 13.0% |
I-5. Largest increases and decreases
- Net increase across comparable companies: KRW 360.0bn.
- The ten largest increases sum to KRW 301.4bn, 83.7% of the net rise.
| Rank | Company | H1 2025 (KRW bn) | H1 2026 (KRW bn) | Change (KRW bn) |
|---|---|---|---|---|
| 1 | LigaChem Biosciences Inc. | 77.3 | 137.1 | +59.8 |
| 2 | Celltrion, Inc. | 229.7 | 284.3 | +54.6 |
| 3 | SK Bioscience Co.,Ltd | 68.0 | 122.4 | +54.4 |
| 4 | Chong Kun Dang Pharmaceutical Corp. | 83.1 | 113.5 | +30.4 |
| 5 | Voronoi, Inc. | 21.4 | 41.7 | +20.4 |
| 6 | Hanmi Pharm. Co., Ltd. | 106.2 | 125.5 | +19.3 |
| 7 | SAM CHUN DANG PHARM CO. LTD | 4.4 | 21.7 | +17.3 |
| 8 | SK biopharmaceuticals Co., Ltd. | 81.6 | 97.3 | +15.7 |
| 9 | YUHAN CORPORATION | 107.3 | 122.2 | +14.8 |
| 10 | JEIL PHARMACEUTICAL CO.,LTD | 21.3 | 35.9 | +14.6 |
| Rank | Company | H1 2025 (KRW bn) | H1 2026 (KRW bn) | Change (KRW bn) |
|---|---|---|---|---|
| 1 | Aprogen, Inc | 30.3 | 9.9 | −20.4 |
| 2 | SEEGENE, INC. | 33.6 | 26.1 | −7.4 |
| 3 | Kolon TissueGene, Inc. | 54.2 | 48.0 | −6.2 |
| 4 | JETEMA Co.,Ltd. | 11.3 | 5.3 | −6.0 |
| 5 | JW PHARMACEUTICAL | 48.8 | 43.1 | −5.6 |
| 6 | DONG-A ST CO.,LTD | 60.4 | 55.2 | −5.1 |
| 7 | ABL Bio Inc. | 53.5 | 48.8 | −4.8 |
| 8 | Cellid Co., Ltd. | 8.4 | 3.7 | −4.7 |
| 9 | Lunit Inc. | 19.0 | 14.4 | −4.6 |
| 10 | HANALL BIOPHARMA CO.,LTD | 18.4 | 14.3 | −4.1 |
I-6. How R&D is accounted for, and what it buys
- Among the 188 companies whose accounting lines reconcile (86% of R&D), 15.8% was capitalised as development cost.
- Capitalisation defers cost, so the same spend weighs less on current profit.
- Government grants totalled KRW 57.3bn.
| Capitalised share | Large | Mid-sized | SME | All |
|---|---|---|---|---|
| Pharma & CDMO | 38.7% (6) | 11.5% (44) | 4.0% (27) | 19.9% (77) |
| Biotech & drug discovery | 42.8% (3) | 4.3% (8) | 4.6% (45) | 12.5% (56) |
| Medical devices | — | 0.1% (18) | 2.0% (32) | 0.5% (50) |
| Medical AI | — | — | 4.5% (3) | 4.5% (3) |
| Healthcare infrastructure | — | — (1) | — (1) | — (2) |
| All | 39.7% (9) | 9.0% (71) | 4.3% (108) | 15.8% (188) |
Only companies whose lines sum to the total (±1%) are included. Grants are not re-allocated.
II. Profitability and funding
R&D against revenue and profit, export sales, and where the money comes from
- 32% of R&D is spent by 114 loss-makers
- Biotech & drug discovery has the highest R&D intensity (30.4%)
- Exports are 27.7% of sales on the sales-table basis (38.5% incl. overseas subsidiaries)
II-1. Revenue, operating profit and R&D intensity
- The 244 companies with financials had H1 revenue of KRW 27.96tn (+13.0% YoY), an operating margin of 10.8% and R&D equal to 10.7% of revenue.
- Biotech & drug discovery has both the highest R&D intensity (30.4%) and the lowest operating margin (-14.9%).
- SMEs: R&D intensity 19.3%, operating margin -11.3%; large companies: 9.8% and 30.7%.
| Sector | Companies (n) | Revenue (KRW bn) | Revenue YoY | Operating margin | R&D / revenue | Loss-making (n) |
|---|---|---|---|---|---|---|
| Pharma & CDMO | 96 | 20,248.7 | +13.6% | 15.1% | 8.4% | 32 |
| Biotech & drug discovery | 65 | 2,954.9 | +12.0% | -14.9% | 30.4% | 48 |
| Medical devices | 66 | 3,966.4 | +10.8% | 10.7% | 8.4% | 26 |
| Medical AI | 10 | 239.2 | +37.9% | -11.4% | 18.1% | 6 |
| Healthcare infrastructure | 7 | 548.8 | +5.0% | 4.2% | 2.2% | 2 |
| All | 244 | 27,958.0 | +13.0% | 10.8% | 10.7% | 114 |
| Size | Companies (n) | Revenue (KRW bn) | Revenue YoY | Operating margin | R&D / revenue | Loss-making (n) |
|---|---|---|---|---|---|---|
| Large | 11 | 7,634.0 | +30.2% | 30.7% | 9.8% | 3 |
| Mid-sized | 88 | 16,944.5 | +6.3% | 6.3% | 9.4% | 23 |
| SME | 145 | 3,379.5 | +19.0% | -11.3% | 19.3% | 88 |
| All | 244 | 27,958.0 | +13.0% | 10.8% | 10.7% | 114 |
Ratios are computed on totals, so large companies weigh more. Company-level distribution: II-2.
II-2. Distribution of R&D intensity
- The median company spends 9.4% of revenue on R&D.
- The median is highest in Biotech & drug discovery (46.4%) and lowest in Pharma & CDMO (5.8%).
- 42 companies exceed 50%, some spending more on R&D than they earn — development-stage companies with little revenue.
| Sector (n) | <5% | 5–10% | 10–20% | 20–50% | 50%+ | No revenue | Not available | Median |
|---|---|---|---|---|---|---|---|---|
| Pharma & CDMO | 41 | 29 | 19 | 2 | 5 | 0 | 2 | 5.8% |
| Biotech & drug discovery | 9 | 5 | 8 | 12 | 29 | 2 | 3 | 46.4% |
| Medical devices | 21 | 13 | 20 | 8 | 5 | 0 | 0 | 9.9% |
| Medical AI | 1 | 1 | 3 | 2 | 3 | 0 | 2 | 19.4% |
| Healthcare infrastructure | 6 | 0 | 0 | 1 | 0 | 0 | 0 | 1.5% |
| All | 78 | 48 | 50 | 25 | 42 | 2 | 7 | 9.4% |
"No revenue": zero half-year revenue. "Not available": no revenue line in the filed financials. From this edition ratios are recomputed on one definition rather than taken as self-reported (see method).
II-3. R&D at loss-making companies
- 114 of 244 companies reported an operating loss.
- They accounted for 32.5% of R&D spend.
- Among SMEs, 88 of 145 were loss-making.
| Sector | Loss-making (n) | All (n) | Share |
|---|---|---|---|
| Pharma & CDMO | 32 | 96 | 33.3% |
| Biotech & drug discovery | 48 | 65 | 73.8% |
| Medical devices | 26 | 66 | 39.4% |
| Medical AI | 6 | 10 | 60.0% |
| Healthcare infrastructure | 2 | 7 | 28.6% |
| All | 114 | 244 | 46.7% |
| Size | Loss-making (n) | All (n) | Share |
|---|---|---|---|
| Large | 3 | 11 | 27.3% |
| Mid-sized | 23 | 88 | 26.1% |
| SME | 88 | 145 | 60.7% |
| All | 114 | 244 | 46.7% |
II-4. Highest R&D intensity
Companies with at least KRW 5bn of half-year revenue, ranked by R&D intensity (small revenue makes ratios swing). LigaChem Biosciences Inc. is highest at 331.1%.
| Rank | Company | Sector | Revenue (KRW bn) | R&D (KRW bn) | R&D / revenue |
|---|---|---|---|---|---|
| 1 | LigaChem Biosciences Inc. | Biotech & drug discovery | 41.4 | 137.1 | 331.1% |
| 2 | SillaJen, Inc. | Biotech & drug discovery | 5.1 | 8.4 | 165.6% |
| 3 | ABL Bio Inc. | Biotech & drug discovery | 32.8 | 48.8 | 148.6% |
| 4 | MEDIPOSTCO.,LTD. | Biotech & drug discovery | 38.2 | 44.0 | 115.1% |
| 5 | Aimed Bio Inc. | Biotech & drug discovery | 28.7 | 24.1 | 84.1% |
| 6 | S.Biomedics Co., Ltd. | Pharma & CDMO | 9.2 | 7.4 | 80.5% |
| 7 | TiumBio Co., Ltd. | Biotech & drug discovery | 7.4 | 5.5 | 73.8% |
| 8 | Cellid Co., Ltd. | Biotech & drug discovery | 5.3 | 3.7 | 69.7% |
| 9 | IMBiologics Corp. | Biotech & drug discovery | 7.2 | 3.7 | 50.8% |
| 10 | NEXTBIOMEDICAL Co., Ltd. | Medical devices | 9.1 | 4.5 | 49.2% |
II-5. Domestic and export sales
- Across the 137 companies whose sales table splits domestic and export sales, exports were 27.7% (the same definition as the Korea Biotechnology Industry Organization survey).
- Adding 35 companies whose split comes from the regional note (including overseas subsidiaries' local sales; Celltrion, Samsung Biologics) gives 38.5% for 172 companies — the figure and tables below use this combined base.
- On the combined base, Medical devices is highest by sector (59.2%) and large companies by size (73.8%).
| Sector | Companies (n) | Domestic (KRW bn) | Export & overseas (KRW bn) | Export & overseas share | From notes (n) |
|---|---|---|---|---|---|
| Pharma & CDMO | 77 | 12,525.1 | 6,874.9 | 35.4% | 17 |
| Biotech & drug discovery | 32 | 590.5 | 439.5 | 42.7% | 7 |
| Medical devices | 49 | 1,179.5 | 1,710.8 | 59.2% | 9 |
| Medical AI | 9 | 151.8 | 119.0 | 43.9% | 2 |
| Healthcare infrastructure | 5 | 329.6 | 113.4 | 25.6% | 0 |
| All | 172 | 14,776.6 | 9,257.6 | 38.5% | 35 |
| Size | Companies (n) | Domestic (KRW bn) | Export & overseas (KRW bn) | Export & overseas share | From notes (n) |
|---|---|---|---|---|---|
| Large | 8 | 1,789.8 | 5,044.2 | 73.8% | 4 |
| Mid-sized | 70 | 11,470.1 | 3,265.6 | 22.2% | 12 |
| SME | 94 | 1,516.6 | 947.8 | 38.5% | 19 |
| All | 172 | 14,776.6 | 9,257.6 | 38.5% | 35 |
The domestic/export split in the half-year sales table is used first (137 companies); where it is absent, the regional revenue note is used (35). The note's overseas revenue includes local sales of overseas subsidiaries and is broader than exports — Celltrion and Samsung Biologics are on the note basis.
II-6. Capital raising — equity and bonds
- From January 2024 to June 2026, 353 equity and bond issues worth KRW 8.95tn were decided.
- Working capital is the main stated use (66.6%); 86.0% of the amount was private or third-party placement.
- Counted at the decision; actual proceeds may be cancelled or reduced.
| Sector | Companies | Raisers | Raised (KRW bn) | 2-yr raised / 2-yr R&D |
|---|---|---|---|---|
| Pharma & CDMO | 98 | 45 | 2,303.3 | 25.8% |
| Biotech & drug discovery | 68 | 45 | 5,007.8 | 114.2% |
| Medical devices | 67 | 31 | 1,129.7 | 71.6% |
| Medical AI | 12 | 7 | 413.9 | 193.5% |
| Healthcare infrastructure | 7 | 4 | 92.9 | 87.6% |
| All | 252 | 132 | 8,947.7 | 59.4% |
12 decisions without a stated amount are counted but not summed. "2-yr raised / 2-yr R&D" divides 2024–2025 decisions by the same companies' 2024–2025 R&D; it does not mean the money funded R&D.
II-7. How loss-makers keep funding research
- 76 of the 114 companies loss-making in H1 2026 (67%) decided an equity or bond issue in 2024–2025; 37 of 130 profitable companies did.
- Loss-makers' 2024–2025 issue decisions equal 142% of their R&D over the same years; for profitable companies, 19%.
- Medical AI is highest at 194% (sectors with 10+ companies).
Grouped by H1 2026 operating result (244 companies with revenue and operating profit, as in II-3), not by results at the time of issue. Counted at the decision; actual proceeds may differ.
III. People
Parent-company headcount, set against R&D. R&D headcount has no standard disclosure
- 88,589 staff at 242 companies, +1.4% year on year
- Medical AI is lowest at -2.7% (sectors with 10+ companies)
III-1. Headcount and change
- The 242 companies with both years employed 88,589, +1.4% year on year.
- Medical devices grew most (+2.4%); Medical AI was lowest (-2.7%), among sectors with ten or more companies.
- R&D change (I-2) and headcount change cover different companies and perimeters (group vs parent), so their pace is not compared directly.
| Sector | Companies (n) | H1 2025 | H1 2026 | Change |
|---|---|---|---|---|
| Pharma & CDMO | 96 | 57,943 | 58,609 | +1.1% |
| Biotech & drug discovery | 66 | 11,211 | 11,375 | +1.5% |
| Medical devices | 62 | 14,621 | 14,971 | +2.4% |
| Medical AI | 11 | 1,648 | 1,604 | -2.7% |
| Healthcare infrastructure | 7 | 1,955 | 2,030 | +3.8% |
| All | 242 | 87,378 | 88,589 | +1.4% |
| Size | Companies (n) | H1 2025 | H1 2026 | Change |
|---|---|---|---|---|
| Large | 11 | 13,131 | 13,733 | +4.6% |
| Mid-sized | 86 | 55,143 | 55,582 | +0.8% |
| SME | 145 | 19,104 | 19,274 | +0.9% |
| All | 242 | 87,378 | 88,589 | +1.4% |
III-2. R&D per employee
- Among the 102 companies reporting R&D on a parent-only basis, H1 R&D per employee was KRW 23m on totals; the company median was KRW 16m.
- Because headcount is parent-only, companies reporting consolidated R&D are excluded — dividing group R&D by parent staff would overstate it.
| Sector | Companies (n) | Per head (KRW m) | Median (KRW m) |
|---|---|---|---|
| Pharma & CDMO | 42 | 18 | 10 |
| Biotech & drug discovery | 34 | 45 | 43 |
| Medical devices | 21 | 15 | 14 |
| Medical AI | 4 | 19 | 17 |
| Healthcare infrastructure | — | — | — |
| All | 102 | 23 | 16 |
| Size | Companies (n) | Per head (KRW m) | Median (KRW m) |
|---|---|---|---|
| Large | 3 | 37 | 11 |
| Mid-sized | 33 | 19 | 13 |
| SME | 66 | 31 | 21 |
| All | 102 | 23 | 16 |
IV. Investment and output
Two years of R&D spend (2024–2025) joined, company by company, to the approvals, trials, publications and patents disclosed over the same period — what R&D-only tallies cannot show.
- The top 10% (26) hold 61% of R&D and 65% of global trials
- Per KRW 10bn, approvals peak in Medical devices, papers in Medical AI
- 34 companies in phase 3 · 25 out-licensing deals
- 7 companies disclosed no output at all
IV-1. Two years of spend and disclosed output, by sector
Pharma & CDMO (97 companies) accounts for 56.8% of 2024–2025 R&D. Per KRW 10bn, the leading sector is Medical devices for approvals, Pharma & CDMO for Korean trials, Medical AI for global trials, Medical AI for publications and Medical AI for patents.
| Sector | Companies (n) | R&D (KRW bn) | approvals (n) | Korean trials (n) | global trials (n) | publications (n) | patents (n) |
|---|---|---|---|---|---|---|---|
| Pharma & CDMO | 97 | 6,332.2 | 1,091 | 231 | 201 | 378 | 1,116 |
| Biotech & drug discovery | 75 | 3,296.1 | 112 | 46 | 45 | 320 | 961 |
| Medical devices | 69 | 1,279.8 | 594 | 4 | 14 | 202 | 1,241 |
| Medical AI | 12 | 182.1 | 51 | 0 | 6 | 169 | 235 |
| Healthcare infrastructure | 7 | 50.2 | 26 | 3 | 1 | 12 | 83 |
| Sector · per KRW 10bn | approvals (n) | Korean trials (n) | global trials (n) | publications (n) | patents (n) |
|---|---|---|---|---|---|
| Pharma & CDMO | 1.72 | 0.36 | 0.32 | 0.60 | 1.91 |
| Biotech & drug discovery | 0.34 | 0.14 | 0.14 | 0.97 | 3.31 |
| Medical devices | 4.64 | 0.03 | 0.11 | 1.58 | 10.66 |
| Medical AI | 2.80 | 0.00 | 0.33 | 9.28 | 15.99 |
| Healthcare infrastructure | 5.18 | 0.60 | 0.20 | 2.39 | 15.11 |
| All | 1.68 | 0.25 | 0.24 | 0.97 | 3.60 |
Sector leaders are chosen among sectors with at least 10 companies — small denominators swing. Patents are published 18 months after filing, so 2023–2024 filings are divided by 2023–2024 R&D.
IV-2. Concentration
The top 10% of spenders (26 companies) account for 61.1% of two-year R&D. They also hold 64.8% of global trial starts and 51.1% of Korean trial authorisations — the costlier the stage, the more concentrated. Approvals (23.2%) and patents (23.8%) are broadly spread.
IV-3. Approvals and trials per KRW 10bn
Companies with at least KRW 5bn of two-year R&D, ranked by approvals (top) and Korean trial authorisations (bottom) per KRW 10bn. This is not an efficiency measure — a generic and a new drug, or a Class 2 certification and a Class 4 approval, each count as one. It shows what form of public record the spend took.
| Rank | Company | Two-year R&D (KRW bn) | approvals (n) | Per KRW 10bn (n) |
|---|---|---|---|---|
| 1 | SINSIN PHARMACEUTICAL Co., LTD. | 5.3 | 24 | 44.9 |
| 2 | DongBang Medical Co., Ltd. | 5.9 | 24 | 40.8 |
| 3 | Precision Biosensor Inc. | 6.2 | 20 | 32.4 |
| 4 | KOREA ARLICO PHARM CO.,LTD. | 10.1 | 30 | 29.8 |
| 5 | CMG Pharmaceutical Co., Ltd. | 17.6 | 52 | 29.6 |
| 6 | Coreline Soft Co., Ltd | 6.1 | 16 | 26.4 |
| 7 | SHINIL PHARMACEUTICAL CO., LTD. | 8.6 | 20 | 23.2 |
| 8 | DIO Corporation | 9.3 | 18 | 19.3 |
| 9 | Yuyu Pharma, Inc. | 8.2 | 15 | 18.3 |
| 10 | DONGSUNG PHARMACEUTICAL CO.,LTD | 8.3 | 14 | 16.8 |
| Rank | Company | Two-year R&D (KRW bn) | Korean trials (n) | Per KRW 10bn (n) |
|---|---|---|---|---|
| 1 | SINSIN PHARMACEUTICAL Co., LTD. | 5.3 | 2 | 3.7 |
| 2 | C&R Research Inc. | 6.3 | 2 | 3.2 |
| 3 | KOREA ARLICO PHARM CO.,LTD. | 10.1 | 3 | 3.0 |
| 4 | REYON PHARMACEUTICAL CO., LTD | 7.7 | 2 | 2.6 |
| 5 | Aprogen Biologics Inc. | 23.7 | 5 | 2.1 |
| 6 | SEOUL PHARMA CO.,LTD | 5.4 | 1 | 1.9 |
| 7 | Daehan Nupharm Co.,Ltd. | 16.8 | 3 | 1.8 |
| 8 | DAEWON PHARMACEUTICAL CO.,LTD | 101.1 | 18 | 1.8 |
| 9 | Boryung Corporation | 124.7 | 22 | 1.8 |
| 10 | Hana Pharm. Co., Ltd. | 29.3 | 5 | 1.7 |
IV-4. Publications per KRW 10bn
On the same basis, PubMed-indexed publications per KRW 10bn. Medical AI companies feature prominently.
| Rank | Company | Two-year R&D (KRW bn) | publications (n) | Per KRW 10bn (n) |
|---|---|---|---|---|
| 1 | 3billion Inc. | 7.7 | 64 | 83.5 |
| 2 | Optipharm.CO.,LTD | 8.9 | 27 | 30.2 |
| 3 | Future Medicine Co., Ltd. | 6.7 | 19 | 28.5 |
| 4 | Coreline Soft Co., Ltd | 6.1 | 16 | 26.4 |
| 5 | NEUROPHET Inc. | 12.7 | 30 | 23.6 |
| 6 | VUNO, Inc. | 11.2 | 22 | 19.7 |
| 7 | HEM Pharma Inc. | 7.1 | 10 | 14.2 |
| 8 | Oncocross Co.,Ltd. | 6.3 | 8 | 12.8 |
| 9 | ORGANOIDSCIENCES LTD. | 11.0 | 13 | 11.9 |
| 10 | DEEPNOID Inc. | 12.3 | 14 | 11.4 |
IV-5. Companies with no disclosed output
7 companies with KRW 26.4bn of two-year R&D had no approval, trial, publication or patent disclosed over the same period (Pharma & CDMO 3 · Medical AI 1 · Healthcare infrastructure 1 · Biotech & drug discovery 1 · Medical devices 1). Many are early-stage or file through overseas partners, so they are not named.
IV-6. Pipeline by phase
- 2024–2025 Korean authorisations (excluding bioequivalence): phase 1 208, phase 2 32, phase 3 43; global starts: phase 1 140, phase 2 29, phase 3 52.
- 224 bioequivalence studies (for generics) are counted separately.
- 34 companies have a phase 3 trial; 53 global phase 3 trials are ongoing.
| Sector | KR P1 | KR P2 | KR P3 | KR other | Gl P1 | Gl P2 | Gl P3 | Gl other | BE |
|---|---|---|---|---|---|---|---|---|---|
| Pharma & CDMO | 177 | 16 | 38 | 0 | 115 | 13 | 47 | 26 | 201 |
| Biotech & drug discovery | 27 | 13 | 5 | 1 | 24 | 13 | 4 | 4 | 13 |
| Medical devices | 3 | 1 | 0 | 0 | 1 | 2 | 1 | 10 | 10 |
| Medical AI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 |
| Healthcare infrastructure | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| All | 208 | 32 | 43 | 1 | 140 | 29 | 52 | 46 | 224 |
Combined phases count at the higher phase. "Other" covers phase 4 and studies without a phase (e.g. device trials); IV-1 totals equal the sum including "other". Global trials only where the company or a confirmed subsidiary is the lead sponsor. Ongoing counts are as of the computation date.
IV-7. Licensing — when research earns money
- From January 2024 to June 2026, 17 companies disclosed 25 out-licensing deals; 23 in-licensing deals and 13 terminations.
- The 15 deals with a disclosed KRW value total KRW 15.26tn; the 17 with a disclosed upfront total KRW 522.9bn. The 3 deals stated only in foreign currency are not summed, and 6 deals kept amounts confidential.
- Headline deal values are mostly contingent milestones; only upfronts and milestones achieved are received.
| Date | Company | Counterparty | Total (KRW bn) | Upfront (KRW bn) |
|---|---|---|---|---|
| 2025-04-07 | ABL Bio Inc. | GSK (GlaxoSmithKline) | 4,110.4 | 73.9 |
| 2025-11-12 | ABL Bio Inc. | Eli Lilly and Company | 3,807.2 | 58.5 |
| 2026-06-01 | Hanmi Pharm. Co., Ltd. | Eli Lilly and Company | 1,897.3 | 112.9 |
| 2024-10-10 | LigaChem Biosciences Inc. | ONO PHARMACEUTICAL CO., LTD. | 943.5 | — |
| 2025-02-07 | OliX Pharmaceuticals, Inc. | Eli lilly and company | 911.7 | — |
| 2026-03-25 | Alteogen Inc. | Biogen International GMBH | 867.5 | 30.0 |
| 2026-05-11 | curacle co., ltd. | Memento Medicines | 781.8 | 5.8 |
| 2025-05-28 | NIBEC CO., LTD. | A US biopharma company (undisc | 595.3 | 10.9 |
| 2024-06-03 | Genome&Company | Debiopharm | 586.4 | 6.9 |
| 2026-01-20 | Alteogen Inc. | Tesaro, Inc. | 420.0 | 29.5 |
| 2024-05-02 | MOA Life Plus Co. Ltd. | Elevai Labs, Inc. | 180.7 | 1.5 |
| 2024-06-26 | ISU Abxis Co., Ltd. | A US oncology developer (undis | 118.5 | 4.2 |
| 2024-09-09 | ENCell Co., Ltd. | Lucy Biotech | 25.9 | 2.0 |
| 2024-11-07 | KANGSTEM BIOTECH CO., LTD. | Yuyoung Pharm | 14.0 | — |
| 2025-12-16 | SyntekaBio,Inc. | Panoros Bioscience | 2.5 | 0.5 |
| 2025-03-04 | AbClon Inc. | TCT Health Technology | n/d | — |
| 2024-07-30 | Alteogen Inc. | Sandoz AG | n/d | — |
| 2024-11-08 | Alteogen Inc. | Daiichi Sankyo | n/d | 28.0 |
| 2025-03-17 | Alteogen Inc. | MedImmune, LLC | n/d | 29.1 |
| 2025-03-17 | Alteogen Inc. | MedImmune Limited | n/d | 36.4 |
| 2026-03-16 | G2GBIO, Inc. | Samsung Bioepis · Epis NexLab | n/d | — |
| 2024-10-10 | LigaChem Biosciences Inc. | ONO PHARMACEUTICAL CO., LTD. | n/d | — |
| 2025-12-16 | OSCOTECInc. | ADEL and Sanofi | n/d | 55.3 |
| 2026-06-01 | OSCOTECInc. | Agios Pharmaceuticals, Inc. | n/d | 37.5 |
| 2025-05-13 | Y-Biologics, Inc | LigaChem Biosciences | n/d | — |
Only KRW amounts stated in the filing are used (no exchange rate applied by us). Amendments, assignments and duplicate filings are excluded. Two deals with the same partner on the same day count separately (LigaChem–ONO: the LCB97 asset deal and the multi-target ADC research deal). Each filing was read and every figure checked against a verbatim quote of the source.
V. The largest spenders up close
The ten largest two-year spenders — trend, financial context and disclosed output
- Celltrion, Inc. leads with KRW 902.4bn over two years
V-1. Celltrion, Inc.
Celltrion, Inc. spent KRW 284.3bn on R&D in H1 2026 (+23.8% YoY), 11.2% of revenue. Over two years it spent KRW 902.4bn; disclosed output over the same period: Approvals 20 · Korean trials 18 · Global trials 13 · Papers 36 · Patents 46.
| Item | Value |
|---|---|
| Sector · size · basis | Pharma & CDMO · Large · consolidated |
| H1 revenue (KRW bn) | 2,538.7 |
| H1 operating profit (KRW bn) | 773.7 |
| Capitalised share of R&D | 55.7% |
| Employees (period end) | 3,172 |
| Export share | 72.6% (note basis) |
V-2. YUHAN CORPORATION
YUHAN CORPORATION spent KRW 122.2bn on R&D in H1 2026 (+13.8% YoY), 10.5% of revenue. Over two years it spent KRW 511.2bn; disclosed output over the same period: Approvals 31 · Korean trials 9 · Global trials 26 · Papers 27 · Patents 55.
| Item | Value |
|---|---|
| Sector · size · basis | Pharma & CDMO · Mid-sized · consolidated |
| H1 revenue (KRW bn) | 1,166.2 |
| H1 operating profit (KRW bn) | 75.7 |
| Capitalised share of R&D | 0.8% |
| Employees (period end) | 2,145 |
| Export share | 19.5% |
V-3. DAEWOONG PHARMA
DAEWOONG PHARMA spent KRW 115.7bn on R&D in H1 2026 (+8.5% YoY), 15.7% of revenue. Over two years it spent KRW 454.5bn; disclosed output over the same period: Approvals 50 · Korean trials 17 · Global trials 21 · Papers 27 · Patents 87.
| Item | Value |
|---|---|
| Sector · size · basis | Pharma & CDMO · Mid-sized · separate |
| H1 revenue (KRW bn) | 735.9 |
| H1 operating profit (KRW bn) | 104.6 |
| Capitalised share of R&D | 10.9% |
| Employees (period end) | 1,972 |
| Export share | 20.6% |
V-4. Hanmi Pharm. Co., Ltd.
Hanmi Pharm. Co., Ltd. spent KRW 125.5bn on R&D in H1 2026 (+18.2% YoY), 14.6% of revenue. Over two years it spent KRW 438.8bn; disclosed output over the same period: Approvals 23 · Korean trials 9 · Global trials 12 · Papers 72 · Patents 114.
| Item | Value |
|---|---|
| Sector · size · basis | Pharma & CDMO · Mid-sized · consolidated |
| H1 revenue (KRW bn) | 860.2 |
| H1 operating profit (KRW bn) | 184.7 |
| Capitalised share of R&D | 7.3% |
| Employees (period end) | 2,424 |
| Export share | 21.4% |
V-5. SAMSUNG EPIS HOLDINGS Co., Ltd.
SAMSUNG EPIS HOLDINGS Co., Ltd. spent KRW 106.0bn on R&D in H1 2026, 12.5% of revenue. Over two years it spent KRW 419.2bn; disclosed output over the same period: Approvals 13 · Korean trials 0 · Global trials 2 · Papers 22 · Patents 10. Its consolidation scope changed (e.g. a demerger), so period values cover different perimeters.
| Item | Value |
|---|---|
| Sector · size · basis | Pharma & CDMO · Large · consolidated |
| H1 revenue (KRW bn) | 845.8 |
| H1 operating profit (KRW bn) | 149.3 |
| Capitalised share of R&D | 34.2% |
| Employees (period end) | 10 |
| Export share | 94.0% |
V-6. GC Biopharma Corp.
GC Biopharma Corp. spent KRW 85.9bn on R&D in H1 2026 (+3.8% YoY), 10.0% of revenue. Over two years it spent KRW 346.6bn; disclosed output over the same period: Approvals 36 · Korean trials 5 · Global trials 3 · Papers 14 · Patents 27.
| Item | Value |
|---|---|
| Sector · size · basis | Pharma & CDMO · Mid-sized · consolidated |
| H1 revenue (KRW bn) | 856.7 |
| H1 operating profit (KRW bn) | 13.5 |
| Capitalised share of R&D | 7.6% |
| Employees (period end) | 2,422 |
| Export share | 32.6% |
V-7. Chong Kun Dang Pharmaceutical Corp.
Chong Kun Dang Pharmaceutical Corp. spent KRW 113.5bn on R&D in H1 2026 (+36.6% YoY), 12.3% of revenue. Over two years it spent KRW 343.2bn; disclosed output over the same period: Approvals 55 · Korean trials 16 · Global trials 22 · Papers 7 · Patents 75.
| Item | Value |
|---|---|
| Sector · size · basis | Pharma & CDMO · Mid-sized · consolidated |
| H1 revenue (KRW bn) | 926.2 |
| H1 operating profit (KRW bn) | 32.7 |
| Capitalised share of R&D | 28.1% |
| Employees (period end) | 2,285 |
| Export share | 4.0% |
V-8. SK biopharmaceuticals Co., Ltd.
SK biopharmaceuticals Co., Ltd. spent KRW 97.3bn on R&D in H1 2026 (+19.2% YoY), 20.5% of revenue. Over two years it spent KRW 335.6bn; disclosed output over the same period: Approvals 0 · Korean trials 0 · Global trials 1 · Papers 3 · Patents 29.
| Item | Value |
|---|---|
| Sector · size · basis | Biotech & drug discovery · Large · consolidated |
| H1 revenue (KRW bn) | 475.3 |
| H1 operating profit (KRW bn) | 186.8 |
| Capitalised share of R&D | — |
| Employees (period end) | 278 |
| Export share | — |
V-9. LigaChem Biosciences Inc.
LigaChem Biosciences Inc. spent KRW 137.1bn on R&D in H1 2026 (+77.4% YoY), 331.1% of revenue. Over two years it spent KRW 330.4bn; disclosed output over the same period: Approvals 0 · Korean trials 0 · Global trials 1 · Papers 3 · Patents 33.
| Item | Value |
|---|---|
| Sector · size · basis | Biotech & drug discovery · Mid-sized · consolidated |
| H1 revenue (KRW bn) | 41.4 |
| H1 operating profit (KRW bn) | -109.4 |
| Capitalised share of R&D | 0.0% |
| Employees (period end) | 190 |
| Export share | — |
V-10. SAMSUNG BIOLOGICS CO.,LTD.
SAMSUNG BIOLOGICS CO.,LTD. spent KRW 81.9bn on R&D in H1 2026, 3.2% of revenue. Over two years it spent KRW 309.0bn; disclosed output over the same period: Approvals 0 · Korean trials 0 · Global trials 0 · Papers 3 · Patents 21. Its consolidation scope changed (e.g. a demerger), so period values cover different perimeters.
| Item | Value |
|---|---|
| Sector · size · basis | Pharma & CDMO · Large · consolidated |
| H1 revenue (KRW bn) | 2,578.0 |
| H1 operating profit (KRW bn) | 1,167.2 |
| Capitalised share of R&D | 0.0% |
| Employees (period end) | 5,573 |
| Export share | 83.3% (note basis) |
What the numbers say
- R&D is concentrated. The top twenty account for 58.2% of H1 spend; on a two-year basis the top 10% (26 companies) account for 61.1%. Sector totals move with these companies.
- 32.5% of R&D comes from loss-making companies — spending not covered by that period's operating profit.
- The same spend is accounted for differently. 15.8% was capitalised overall, with wide differences by sector and company — relevant when comparing profits.
- Self-reported ratios are not always comparable. For 11 companies the disclosed R&D ratio departs from the filing form's own formula (pre-grant R&D ÷ revenue). This report recomputes all ratios on one definition.
Method and limits
R&D spend — the "total R&D expense" line of half-year and annual filings, before government grants, consolidated where available. Only values that pass a cross-check (e.g. against the disclosed ratio) are used: a verified census, not a sample.
Non-healthcare companies excluded — 19 companies whose company-wide R&D is mostly unrelated to healthcare: AHNLAB,INC. (security software) · Chunbo Co., Ltd. (battery & display materials) · CJ CHEILJEDANG CORP. (food) · COSMAX BTI, INC. (cosmetics holding company) · COSMAX NBT, INC. (dietary supplements) · HLSCIENCE Co., LTD (dietary supplements) · HYUNDAI ELEVATOR CO.,LTD (elevators) · INTOPS CO., LTD. (handset & appliance parts) · KOLMAR KOREA CO.,LTD (cosmetics contract manufacturing) · Kwangdong Healthbio Co., Ltd. (dietary supplements) · NOVAREX Co., Ltd. (dietary supplements) · NUON CO., LTD. (dietary supplements) · PAKERS CO., Ltd. (printer parts & lighting) · RN2 Technologies Co., Ltd. (telecom components) · S&D Co., Ltd (supplement ingredients) · SBSUNGBO Co., Ltd. (agrochemicals) · SK Innovation Co., Ltd. (refining & batteries) · WonIk Co.,LTD (quartz & semiconductor parts) · WOOREE BIO CO., LTD (dietary supplements).
Holding companies and parents — 10 companies that consolidate listed subsidiaries (nine holding companies and SK Chemicals, parent of SK bioscience) are excluded to avoid double counting: DAEWOONG CO.,LTD · CHONGKUNDANG HOLDINGS CORP. · GC Corp. · JW HOLDINGS CORPORATION · JEIL PHARMA HOLDINGS INC. · ILDONG HOLDINGS CO.,LTD · Huons Global Co., Ltd. · Dong-A Socio Holdings Co.,Ltd · Hanmi Science Co.,Ltd · SK Chemicals Co., Ltd.. Samsung Epis Holdings, whose subsidiary is unlisted, is included.
Year-on-year comparison — only companies with both half-year values on the same consolidation basis. Samsung Biologics (scope changed by the November 2025 demerger) and Samsung Epis Holdings (no prior-year value) are excluded from the comparison.
Output — approvals: MFDS Class 2 device certifications, Class 3–4 device approvals and drug approvals, plus US FDA 510(k) and drug approvals. Class 1 devices, which are only notified without review (242 in the period), are not counted as approvals. Korean trials: MFDS trial authorisations. Global trials: ClinicalTrials.gov start dates. Publications: PubMed author affiliation. Patents: KIPRIS filings, domestic and foreign. Window 2024–2025; patents 2023–2024.
Matching and subsidiaries — records are matched by business registration number or exact corporate name; similarity matching is never used. Approvals, trials and patents filed by subsidiaries whose control is confirmed in filings are counted under the listed parent. Publications are counted by the listed company's own author affiliation only and exclude subsidiary-affiliated papers — except Samsung Epis Holdings, a holding company whose research is carried out entirely by its wholly owned subsidiary Samsung Bioepis, which is counted by that affiliation.
Direction of error — approvals filed by overseas affiliates or partners, CRO-sponsored trials, records of unconfirmed subsidiaries, papers published under a subsidiary's affiliation and global trials whose sponsor name differs sharply from the company name can be missed (undercount). Conversely, patents are counted per filing, so one invention filed in several countries counts several times (overcount), and exact-name matching can rarely attach the wrong company. In this edition 465 global trials at 12 companies, previously missed through name variants, were linked after source checks.
Company size — as each company declares it in its periodic filing (SME / mid-sized status). SMEs meet the Framework Act on SMEs criteria (sector revenue thresholds — KRW 80bn for drug and device manufacturing — total assets under KRW 500bn, independence); mid-sized companies meet the Mid-sized Enterprises Act criteria; large companies are neither. A statutory three-year grace period means some SMEs have large revenue.
Financials — half-year revenue and operating profit from the DART financial API, on the same consolidated or separate basis as each company's R&D. 1,016 values match the XBRL in the filings, a consistency check within one source that cannot catch currency or unit errors — non-KRW filers are screened out separately.
R&D intensity — total R&D expense before grants ÷ revenue × 100, the formula set by the filing form. For 11 companies the self-reported ratio departs from it (usually computed after grants), so the recomputed value is used. The first edition (September 2026) used self-reported ratios for sector medians; from this edition all ratios are recomputed.
Accounting and nature — from the same table as the R&D total, only where lines sum to the total (±1%). Grants are not re-allocated across lines.
Domestic vs export — the sales table's split (domestic + export = total = reported revenue, ±3%) first; otherwise the regional revenue note (domestic / overseas), which includes overseas subsidiaries' local sales. The CSV states which source each company uses.
Headcount — parent-company staff at period end, including fixed-term. Subtotal rows are removed by structure (a row equal to the sum of the others), not by label, to avoid double counting. R&D headcount has no standardised disclosure and is not reported.
Pipeline — Korean MFDS trial authorisations (2024–2025) and ClinicalTrials.gov studies with the company as lead sponsor, by start date (2024–2025). Bioequivalence studies, run to launch generics, are counted separately from Korean trials (the first edition mixed them). Combined phases count at the higher one.
Capital raising — rights issues, placements, convertible bonds, bonds with warrants and exchangeable bonds decided in material-event reports (Jan 2024–Jun 2026, board resolution date). Amounts sum the stated uses of proceeds and count at the decision; actual proceeds may differ. Bonus issues are excluded. "Raised / R&D" does not imply the money funded R&D.
Licensing — each KRX disclosure of material management matters was read; only new deals are counted (amendments, assignments and duplicates excluded). Only KRW amounts stated in the filing are used; foreign-currency-only amounts are left blank. Headline values are mostly contingent milestones.
Population — of the 422 index companies, 281 have an R&D table that passed our cross-check, 65 did not pass, 60 have no R&D disclosure or DART code, and 16 were excluded (non-December year-end or holding company). Of the 270 with a verified H1 2026 value, 18 non-healthcare companies are removed, leaving 252. Companies verified but without an H1 value (e.g. those filing an annual report instead) appear only in the two-year metrics (IV). Financials are used only when filed in KRW (Kolon TissueGene reports in US dollars and is left out of financial tables).
Korean reports compared — "the Korean reports we reviewed" are the Korea Biotechnology Industry Organization's listed-company survey, KBIOIS in-depth analyses and briefs, and press tallies of half-year R&D (e.g. Medipana). Where a consolidated subsidiary is separately listed (e.g. Celltrion and Celltrion Pharm), both are counted unless the parent is a holding company, so totals may overlap slightly.
Table cells — cells with fewer than three companies are shown as "—": they would reveal a single company and are not representative. Ratios on totals weigh large companies more.
Edition history — first edition 2026-09-24 (R&D and disclosed output) → full edition 2026-10-07 (this one). Added: financials, people, export sales, capital raising, pipeline and licensing; R&D intensity recomputed with the filing-form formula; bioequivalence removed from Korean trials; 465 global trials at 12 companies and three sector classifications corrected. Corrections are logged.
Verification — ranked figures were recounted from the raw collection files. R&D was checked against the ratio companies state in the same table; capital raising against the count of decision filings in the disclosure index; licensing amounts against verbatim quotes of the filing (independent paths). Financial API values were also matched to the filings' XBRL, which confirms consistency within one source. Reported errors are recomputed and corrected with a visible history.
Appendix. Company table
All 252 companies, ordered by H1 2026 R&D spend: investment and financials above, two-year output below (same ranking). Company data with more columns (revenue, operating profit, headcount, export share) can be downloaded as CSV from "Download company data" at the top of the report or at medicalaialliance.org/reports/rnd-invest-2026h1.csv.
| Rank | Company | Sector | Size | H1 2026 (KRW bn) | YoY | R&D / revenue |
|---|---|---|---|---|---|---|
| 1 | Celltrion, Inc. | Pharma & CDMO | Large | 284.3 | +23.8% | 11.2% |
| 2 | LigaChem Biosciences Inc. | Biotech & drug discovery | Mid-sized | 137.1 | +77.4% | 331.1% |
| 3 | Hanmi Pharm. Co., Ltd. | Pharma & CDMO | Mid-sized | 125.5 | +18.2% | 14.6% |
| 4 | SK Bioscience Co.,Ltd | Biotech & drug discovery | Large | 122.4 | +80.0% | 37.7% |
| 5 | YUHAN CORPORATION | Pharma & CDMO | Mid-sized | 122.2 | +13.8% | 10.5% |
| 6 | DAEWOONG PHARMA | Pharma & CDMO | Mid-sized | 115.7 | +8.5% | 15.7% |
| 7 | Chong Kun Dang Pharmaceutical Corp. | Pharma & CDMO | Mid-sized | 113.5 | +36.6% | 12.3% |
| 8 | SAMSUNG EPIS HOLDINGS Co., Ltd. | Pharma & CDMO | Large | 106.0 | — | 12.5% |
| 9 | SK biopharmaceuticals Co., Ltd. | Biotech & drug discovery | Large | 97.3 | +19.2% | 20.5% |
| 10 | GC Biopharma Corp. | Pharma & CDMO | Mid-sized | 85.9 | +3.8% | 10.0% |
| 11 | SAMSUNG BIOLOGICS CO.,LTD. | Pharma & CDMO | Large | 81.9 | — | 3.2% |
| 12 | DONG-A ST CO.,LTD | Pharma & CDMO | Mid-sized | 55.2 | -8.5% | 12.9% |
| 13 | ABL Bio Inc. | Biotech & drug discovery | SME | 48.8 | -8.9% | 148.6% |
| 14 | Kolon TissueGene, Inc. | Biotech & drug discovery | Large | 48.0 | -11.4% | — |
| 15 | MEDIPOSTCO.,LTD. | Biotech & drug discovery | SME | 44.0 | +28.3% | 115.1% |
| 16 | JW PHARMACEUTICAL | Pharma & CDMO | Mid-sized | 43.1 | -11.5% | 10.2% |
| 17 | SD BIOSENSOR INC. | Medical devices | Mid-sized | 42.9 | +18.8% | 11.3% |
| 18 | HK inno.N Corporation | Pharma & CDMO | Mid-sized | 42.6 | +12.8% | 8.1% |
| 19 | Voronoi, Inc. | Biotech & drug discovery | SME | 41.7 | +95.4% | — |
| 20 | JEIL PHARMACEUTICAL CO.,LTD | Pharma & CDMO | Mid-sized | 35.9 | +68.4% | 13.0% |
| 21 | Orum Therapeutics, Inc. | Biotech & drug discovery | SME | 35.2 | +62.5% | 1,000%+ |
| 22 | Boryung Corporation | Pharma & CDMO | Mid-sized | 28.6 | -10.4% | 5.4% |
| 23 | SEEGENE, INC. | Medical devices | Mid-sized | 26.1 | -22.2% | 9.9% |
| 24 | Aimed Bio Inc. | Biotech & drug discovery | SME | 24.1 | — | 84.1% |
| 25 | IL DONG PHARMACEUTICAL CO., LTD. | Pharma & CDMO | Mid-sized | 23.9 | +38.6% | 8.3% |
| 26 | PharmaResearch Co., Ltd. | Medical devices | Mid-sized | 23.8 | +48.8% | 7.3% |
| 27 | DAEWON PHARMACEUTICAL CO.,LTD | Pharma & CDMO | Mid-sized | 23.6 | -4.5% | 7.6% |
| 28 | Medy-Tox Inc. | Pharma & CDMO | Mid-sized | 22.3 | +1.1% | 17.3% |
| 29 | SAM CHUN DANG PHARM CO. LTD | Pharma & CDMO | Mid-sized | 21.7 | +390.3% | 16.0% |
| 30 | HLB Co.,LTD. | Biotech & drug discovery | Mid-sized | 21.7 | -15.8% | 46.5% |
| 31 | HUONS CO., LTD. | Pharma & CDMO | Mid-sized | 21.5 | +9.1% | 7.4% |
| 32 | GI Innovation Inc. | Biotech & drug discovery | SME | 21.2 | +26.8% | — |
| 33 | i-SENS, Inc. | Medical devices | Mid-sized | 20.7 | +39.4% | 12.6% |
| 34 | OliX Pharmaceuticals, Inc. | Biotech & drug discovery | SME | 18.5 | +40.7% | — |
| 35 | KOREA UNITED PHARM INC | Biotech & drug discovery | Mid-sized | 17.6 | +3.6% | 11.6% |
| 36 | ILYANG PHARMACEUTICAL CO.,LTD | Biotech & drug discovery | Mid-sized | 17.4 | +21.5% | 13.3% |
| 37 | DongKookPharmaceuticalCo.,Ltd. | Pharma & CDMO | Mid-sized | 17.3 | +15.7% | 4.0% |
| 38 | Qurient Co., Ltd. | Biotech & drug discovery | SME | 16.5 | +64.7% | 429.3% |
| 39 | SAMJIN PHARMACEUTICAL CO.,LTD | Pharma & CDMO | Mid-sized | 16.3 | -3.1% | 11.1% |
| 40 | Mezzion Pharma Co., Ltd. | Biotech & drug discovery | SME | 15.8 | +128.6% | 375.2% |
| 41 | KYONGBO PHARMACEUTICAL CO., LTD. | Pharma & CDMO | Mid-sized | 15.2 | +42.8% | 10.8% |
| 42 | OSCOTECInc. | Biotech & drug discovery | SME | 15.0 | +20.6% | 26.7% |
| 43 | BUKWANG PHARMACEUTICAL IND CO.,LTD | Pharma & CDMO | Large | 14.9 | +27.9% | 14.3% |
| 44 | CLASSYS Inc. | Medical devices | Mid-sized | 14.6 | +37.3% | 7.6% |
| 45 | Lunit Inc. | Medical AI | SME | 14.4 | -24.3% | 31.5% |
| 46 | HANALL BIOPHARMA CO.,LTD | Pharma & CDMO | Mid-sized | 14.3 | -22.4% | 16.9% |
| 47 | ST PHARM CO., LTD. | Pharma & CDMO | Mid-sized | 13.8 | +18.8% | 7.9% |
| 48 | Rznomics Inc. | Biotech & drug discovery | SME | 13.5 | — | 1,000%+ |
| 49 | GC CELL CORPORATION | Biotech & drug discovery | Mid-sized | 13.4 | -2.4% | 16.9% |
| 50 | D&D Pharmatech Inc. | Biotech & drug discovery | SME | 13.1 | +0.9% | 1,000%+ |
| 51 | Genexine, Inc. | Biotech & drug discovery | SME | 12.8 | +19.9% | 920.1% |
| 52 | Inventage Lab Inc. | Biotech & drug discovery | SME | 12.7 | +30.6% | 1,000%+ |
| 53 | Vieworks Co., Ltd. | Medical devices | Mid-sized | 12.5 | -3.9% | 10.3% |
| 54 | Curocell Inc. | Biotech & drug discovery | SME | 12.2 | -24.2% | — |
| 55 | DONGWHA PHARM.CO.,LTD | Pharma & CDMO | Mid-sized | 12.0 | -3.5% | 4.5% |
| 56 | Boditech Med Inc. | Medical devices | Mid-sized | 11.8 | +24.8% | 12.6% |
| 57 | BIONEERCORPORATION | Medical devices | Mid-sized | 11.3 | +54.9% | 6.3% |
| 58 | HANDOK Inc. | Pharma & CDMO | Mid-sized | 11.2 | -1.7% | 4.1% |
| 59 | SHINPOONG PHARMACEUTICAL CO.,LTD | Pharma & CDMO | Mid-sized | 10.9 | — | 9.2% |
| 60 | Chabiotech Co.,Ltd. | Biotech & drug discovery | Mid-sized | 10.8 | -11.0% | 1.7% |
| 61 | Samyang Biopharm Corporation | Medical devices | Mid-sized | 10.3 | — | 15.4% |
| 62 | OSANG HEALTHCARE CO.,LTD. | Medical devices | Mid-sized | 10.0 | -3.9% | 23.8% |
| 63 | Aprogen, Inc | Pharma & CDMO | Mid-sized | 9.9 | -67.4% | 13.7% |
| 64 | Huvitz Co., Ltd. | Medical devices | Mid-sized | 9.8 | -8.5% | 17.3% |
| 65 | Peptron, Inc. | Biotech & drug discovery | SME | 9.6 | +25.9% | 280.4% |
| 66 | EuBiologics Co., Ltd. | Biotech & drug discovery | SME | 9.5 | +46.7% | 19.4% |
| 67 | Hana Pharm. Co., Ltd. | Pharma & CDMO | Mid-sized | 9.5 | +14.8% | 7.7% |
| 68 | LivsMed Inc. | Medical devices | SME | 9.4 | — | 41.3% |
| 69 | Hugel, Inc. | Pharma & CDMO | Large | 8.7 | +21.2% | 3.4% |
| 70 | AHN-GOOK PHARMACEUTICAL Co., Ltd. | Pharma & CDMO | Mid-sized | 8.7 | -8.7% | 4.6% |
| 71 | SillaJen, Inc. | Biotech & drug discovery | SME | 8.4 | +62.1% | 165.6% |
| 72 | Celltrion Pharm Inc. | Pharma & CDMO | Large | 8.4 | +20.0% | 3.0% |
| 73 | BioNote, Inc. | Medical devices | Mid-sized | 8.3 | +17.0% | 12.1% |
| 74 | DRTECH Corporation | Medical devices | SME | 8.3 | +23.7% | 12.0% |
| 75 | ValueAddedTechnologyCo.,Ltd. | Medical devices | Mid-sized | 8.1 | +39.3% | 6.1% |
| 76 | WHANIN PHARM CO.,LTD | Pharma & CDMO | Mid-sized | 8.0 | -31.0% | 5.6% |
| 77 | CJ Bioscience | Biotech & drug discovery | Large | 7.9 | -14.3% | 469.9% |
| 78 | ISU Abxis Co., Ltd. | Biotech & drug discovery | Mid-sized | 7.7 | -2.8% | 31.7% |
| 79 | KANGSTEM BIOTECH CO., LTD. | Biotech & drug discovery | SME | 7.6 | — | 527.3% |
| 80 | QuadMedicine Inc. | Pharma & CDMO | SME | 7.5 | +2.8% | — |
| 81 | S.Biomedics Co., Ltd. | Pharma & CDMO | SME | 7.4 | +59.1% | 80.5% |
| 82 | MYUNGIN PHARM.CO., LTD | Pharma & CDMO | Mid-sized | 7.4 | — | 5.0% |
| 83 | KOLON LIFE SCIENCE Inc. | Pharma & CDMO | Large | 7.2 | +4.4% | 7.2% |
| 84 | AbClon Inc. | Biotech & drug discovery | SME | 7.1 | -4.8% | 334.5% |
| 85 | KWANGDONG PHARMACEUTICAL CO.,LTD | Pharma & CDMO | Mid-sized | 7.0 | -2.4% | 1.4% |
| 86 | STCUBE | Biotech & drug discovery | SME | 7.0 | +50.9% | 242.8% |
| 87 | YUNGJIN PHARM. CO., LTD | Pharma & CDMO | Large | 6.8 | +15.8% | 5.4% |
| 88 | SELVAS AI Inc. | Medical AI | SME | 6.7 | +32.1% | 11.1% |
| 89 | CKD Bio Corp. | Pharma & CDMO | Mid-sized | 6.6 | +5.4% | 8.0% |
| 90 | PharmGen Science, Inc. | Pharma & CDMO | Mid-sized | 6.4 | — | 7.0% |
| 91 | KolmarBNH Co., Ltd | Healthcare infrastructure | Mid-sized | 6.1 | +23.3% | 2.3% |
| 92 | MedPacto, Inc. | Biotech & drug discovery | SME | 5.9 | — | 249.3% |
| 93 | GENORAY Co., LTD. | Medical devices | SME | 5.9 | -3.5% | 11.3% |
| 94 | Genome&Company | Biotech & drug discovery | SME | 5.9 | -8.6% | 48.9% |
| 95 | meerecompanyIncorporated | Medical devices | SME | 5.8 | -14.4% | 12.9% |
| 96 | KyungdongPharm | Pharma & CDMO | Mid-sized | 5.7 | -8.6% | 5.7% |
| 97 | InBody Co., Ltd. | Medical devices | Mid-sized | 5.6 | — | 3.9% |
| 98 | TiumBio Co., Ltd. | Biotech & drug discovery | SME | 5.5 | +11.6% | 73.8% |
| 99 | JETEMA Co.,Ltd. | Medical devices | SME | 5.3 | -53.5% | 14.6% |
| 100 | Humedix Co., Ltd. | Pharma & CDMO | Mid-sized | 5.2 | +4.7% | 5.7% |
| 101 | ENCell Co., Ltd. | Pharma & CDMO | SME | 5.1 | — | 433.8% |
| 102 | Daehan Nupharm Co.,Ltd. | Pharma & CDMO | Mid-sized | 4.9 | -28.2% | 4.4% |
| 103 | SUHEUNG CO.,LTD. | Biotech & drug discovery | Mid-sized | 4.8 | +7.9% | 2.3% |
| 104 | FutureChem Co., Ltd. | Pharma & CDMO | SME | 4.8 | +87.8% | 44.7% |
| 105 | DAE HWA PHARM CO., LTD | Pharma & CDMO | Mid-sized | 4.7 | -11.0% | 6.0% |
| 106 | WON TECH CO.,Ltd. | Medical devices | Mid-sized | 4.6 | — | 5.2% |
| 107 | CUREXO, INC. | Medical devices | Mid-sized | 4.5 | -5.2% | 11.4% |
| 108 | NEXTBIOMEDICAL Co., Ltd. | Medical devices | SME | 4.5 | +15.6% | 49.2% |
| 109 | Shaperon Inc. | Biotech & drug discovery | SME | 4.2 | -5.0% | 1,000%+ |
| 110 | NEUROPHET Inc. | Medical AI | SME | 4.1 | — | 325.4% |
| 111 | SEERS Co., Ltd. | Medical AI | SME | 4.1 | +62.2% | 6.7% |
| 112 | G2GBIO, Inc. | Pharma & CDMO | SME | 3.9 | +0.4% | 202.0% |
| 113 | CMG Pharmaceutical Co., Ltd. | Pharma & CDMO | SME | 3.9 | -15.0% | 7.3% |
| 114 | Kukje Pharma Co., Ltd. | Pharma & CDMO | Mid-sized | 3.9 | — | 4.2% |
| 115 | HLB PHARMACEUTICAL CO., LTD. | Biotech & drug discovery | SME | 3.8 | +33.9% | 3.0% |
| 116 | curacle co., ltd. | Biotech & drug discovery | SME | 3.8 | — | 46.2% |
| 117 | DENTIUM | Medical devices | Mid-sized | 3.8 | -15.1% | 3.3% |
| 118 | Pharmicell Co.,Ltd. | Biotech & drug discovery | SME | 3.7 | +7.1% | 4.9% |
| 119 | Daebonglsco.,Ltd | Pharma & CDMO | SME | 3.7 | +2.3% | 5.9% |
| 120 | Cellid Co., Ltd. | Biotech & drug discovery | SME | 3.7 | -56.1% | 69.7% |
| 121 | IMBiologics Corp. | Biotech & drug discovery | SME | 3.7 | — | 50.8% |
| 122 | INFINITT Healthcare Co., Ltd. | Medical AI | SME | 3.6 | -2.1% | 14.4% |
| 123 | MEDIANA Co.,LTD | Medical devices | SME | 3.6 | — | 9.6% |
| 124 | KOREA ARLICO PHARM CO.,LTD. | Medical devices | Mid-sized | 3.5 | +50.1% | 3.7% |
| 125 | ORGANOIDSCIENCES LTD. | Biotech & drug discovery | SME | 3.4 | +19.4% | 464.4% |
| 126 | Sam-A Pharm. Co. Ltd | Pharma & CDMO | SME | 3.4 | +36.9% | 9.3% |
| 127 | Synergy Innovation Co., Ltd. | Medical devices | SME | 3.4 | — | 5.8% |
| 128 | ARIBIOLAB | Biotech & drug discovery | SME | 3.3 | -27.6% | 1,000%+ |
| 129 | CORESTEMCHEMON Inc. | Pharma & CDMO | SME | 3.3 | -33.5% | 33.4% |
| 130 | Tego Science, Inc. | Biotech & drug discovery | SME | 3.2 | +85.7% | 99.5% |
| 131 | Bio Solution Co.,Ltd. | Biotech & drug discovery | SME | 3.1 | -20.9% | 36.5% |
| 132 | THERAGEN ETEX CO.,LTD. | Pharma & CDMO | Mid-sized | 3.0 | — | 2.2% |
| 133 | JW LIFESCIENCE CORPORATION | Pharma & CDMO | Mid-sized | 3.0 | +3.3% | 2.6% |
| 134 | Cellbion Co., Ltd | Pharma & CDMO | SME | 3.0 | +18.4% | 274.5% |
| 135 | VUNO, Inc. | Medical AI | SME | 3.0 | -0.7% | 24.4% |
| 136 | Noul Co., Ltd. | Medical devices | SME | 2.9 | -28.7% | 219.1% |
| 137 | DEEPNOID Inc. | Medical AI | SME | 2.9 | +32.5% | 173.3% |
| 138 | QuantaMatrix Incorporated | Medical devices | SME | 2.8 | — | 202.2% |
| 139 | NIBEC CO., LTD. | Medical devices | SME | 2.8 | -41.2% | 24.3% |
| 140 | Y-Biologics, Inc | Biotech & drug discovery | SME | 2.7 | — | 149.5% |
| 141 | L&C BIO Co., Ltd | Pharma & CDMO | SME | 2.7 | +35.7% | 4.8% |
| 142 | SAMIL PHARMACEUTICAL CO.,LTD | Pharma & CDMO | Mid-sized | 2.6 | — | 2.6% |
| 143 | KOMIPHARM INTERNATIONAL CO., LTD. | Pharma & CDMO | SME | 2.5 | +43.4% | 8.8% |
| 144 | CG Invites Co., Ltd. | Biotech & drug discovery | SME | 2.5 | -30.8% | 28.2% |
| 145 | Micro Digital Co., Ltd. | Medical devices | SME | 2.5 | — | 67.2% |
| 146 | HEM Pharma Inc. | Healthcare infrastructure | SME | 2.4 | +16.3% | 25.6% |
| 147 | CELL BIOTECH CO ., LTD | Pharma & CDMO | SME | 2.4 | -0.1% | 8.5% |
| 148 | Amicogen, Inc. | Biotech & drug discovery | SME | 2.4 | -35.2% | 9.4% |
| 149 | SyntekaBio,Inc. | Medical AI | SME | 2.4 | +119.6% | 284.9% |
| 150 | IT-CHEM Co., Ltd. | Pharma & CDMO | SME | 2.3 | — | 8.4% |
| 151 | MYUNGMOON PHARM CO.,LTD | Pharma & CDMO | Mid-sized | 2.3 | +8.7% | 2.3% |
| 152 | COSMO ROBOTICS CO., Ltd | Medical devices | SME | 2.3 | — | 91.7% |
| 153 | METABIOMED.CO.,LTD | Medical devices | SME | 2.3 | — | 4.5% |
| 154 | iNtRON Biotechnology, Inc. | Biotech & drug discovery | SME | 2.3 | — | 58.2% |
| 155 | Xcell Therapeutics Inc. | Pharma & CDMO | SME | 2.2 | +45.7% | 75.6% |
| 156 | CAREGEN CO.,LTD. | Biotech & drug discovery | SME | 2.2 | +23.7% | 5.3% |
| 157 | SELVAS Healthcare, Inc. | Medical devices | SME | 2.2 | +11.5% | 14.7% |
| 158 | SHINIL PHARMACEUTICAL CO., LTD. | Pharma & CDMO | SME | 2.2 | — | — |
| 159 | Kolmar BioTech, Inc. | Pharma & CDMO | Mid-sized | 2.1 | — | 9.7% |
| 160 | MITECH CO.,LTD. | Medical devices | SME | 2.1 | — | 5.8% |
| 161 | 3billion Inc. | Biotech & drug discovery | SME | 2.1 | — | 29.1% |
| 162 | T&L Co., LTD. | Medical devices | SME | 2.0 | +4.5% | 2.0% |
| 163 | Optipharm.CO.,LTD | Medical devices | Mid-sized | 2.0 | -3.2% | 16.9% |
| 164 | ANTEROGEN CO., LTD. | Biotech & drug discovery | SME | 2.0 | +13.0% | 46.4% |
| 165 | REYON PHARMACEUTICAL CO., LTD | Pharma & CDMO | Mid-sized | 2.0 | +31.7% | 2.8% |
| 166 | HLB PANAGENE Co., LTD. | Medical devices | SME | 2.0 | -13.5% | 29.1% |
| 167 | Eutilex Co.,Ltd. | Biotech & drug discovery | SME | 2.0 | — | 110.7% |
| 168 | NanoenTek,Inc. | Medical devices | SME | 1.9 | +3.5% | 8.5% |
| 169 | HLB Genex, Inc. | Pharma & CDMO | SME | 1.9 | — | 14.9% |
| 170 | SAMSUNG PHARMACEUTICAL.CO.,Ltd. | Pharma & CDMO | SME | 1.9 | +17.5% | 10.2% |
| 171 | ASTERASYS Co., Ltd. | Medical devices | SME | 1.9 | +35.7% | 10.0% |
| 172 | BioPlus Co., Ltd | Pharma & CDMO | SME | 1.9 | +13.8% | 3.6% |
| 173 | Corentec Co., Ltd. | Medical devices | SME | 1.8 | +1.3% | 4.7% |
| 174 | Binex Co., Ltd. | Pharma & CDMO | Mid-sized | 1.8 | +183.7% | 2.4% |
| 175 | DIO Corporation | Medical devices | Mid-sized | 1.7 | -31.8% | 4.1% |
| 176 | KUKJEON Co.,Ltd | Pharma & CDMO | SME | 1.7 | +9.0% | 2.3% |
| 177 | JW SHINYAK CORPORATION | Biotech & drug discovery | Mid-sized | 1.7 | — | 4.0% |
| 178 | CU MEDICAL SYSTEMS Inc. | Medical devices | SME | 1.7 | +33.6% | 4.8% |
| 179 | PROTIA INC. | Medical devices | SME | 1.7 | +25.4% | 18.1% |
| 180 | T&R Biofab Co., Ltd | Biotech & drug discovery | SME | 1.6 | -27.3% | 9.0% |
| 181 | DONGSUNG PHARMACEUTICAL CO.,LTD | Pharma & CDMO | Mid-sized | 1.6 | -10.4% | 4.0% |
| 182 | Icure Pharmaceutical Incorporation | Healthcare infrastructure | SME | 1.6 | +10.0% | 2.3% |
| 183 | Gencurix Inc. | Medical devices | SME | 1.6 | — | 31.4% |
| 184 | Aprogen Biologics Inc. | Pharma & CDMO | Mid-sized | 1.6 | — | 6.9% |
| 185 | JPI Healthcare Co., Ltd. | Medical devices | SME | 1.6 | -23.1% | 6.9% |
| 186 | Oncocross Co.,Ltd. | Medical AI | SME | 1.6 | -12.9% | — |
| 187 | VIVOZON PHARMACEUTICAL CO., LTD. | Pharma & CDMO | SME | 1.5 | -24.7% | 5.6% |
| 188 | Precision Biosensor Inc. | Medical devices | SME | 1.5 | +0.7% | 11.3% |
| 189 | Coreline Soft Co., Ltd | Medical AI | SME | 1.5 | -1.9% | — |
| 190 | Yuyu Pharma, Inc. | Pharma & CDMO | Mid-sized | 1.4 | -35.3% | 2.7% |
| 191 | ENZYCHEM LIFESCIENCES CORPORATION | Biotech & drug discovery | SME | 1.4 | -26.7% | 3.7% |
| 192 | GC Medical Science Corporation | Medical devices | Mid-sized | 1.4 | -19.5% | 2.8% |
| 193 | MEKICS Co., Ltd | Medical devices | SME | 1.4 | — | 18.8% |
| 194 | DongKook Life Science Co., Ltd. | Medical devices | Mid-sized | 1.4 | +22.8% | 2.4% |
| 195 | Acryl Inc. | Medical AI | SME | 1.4 | — | 11.4% |
| 196 | Raphas Co., Ltd. | Medical devices | SME | 1.4 | — | 9.5% |
| 197 | SINSIN PHARMACEUTICAL Co., LTD. | Pharma & CDMO | SME | 1.3 | -9.1% | 2.1% |
| 198 | SEOUL PHARMA CO.,LTD | Pharma & CDMO | Mid-sized | 1.3 | -7.7% | 5.6% |
| 199 | Plasmapp Co., Ltd. | Medical devices | SME | 1.3 | -23.5% | 23.2% |
| 200 | CHOONG ANG VACCINE LABORATORY | Biotech & drug discovery | SME | 1.3 | -5.0% | 5.3% |
| 201 | JIN YANG PHARMACEUTICAL. CO., LTD | Pharma & CDMO | Mid-sized | 1.3 | +11.1% | 2.0% |
| 202 | GFC Life Science Co., Ltd. | Biotech & drug discovery | SME | 1.3 | +36.3% | 12.2% |
| 203 | GENEMATRIX INC. | Biotech & drug discovery | SME | 1.3 | -13.8% | 23.4% |
| 204 | AMINOLOGICS CO.,LTD. | Pharma & CDMO | SME | 1.2 | +13.7% | 8.9% |
| 205 | Daejung Chemicals & Metals Co., Ltd | Pharma & CDMO | SME | 1.2 | +2.2% | 1.9% |
| 206 | Dynamic solution Co.,Ltd. | Medical devices | SME | 1.1 | -24.2% | 15.6% |
| 207 | Pangen Biotech Inc. | Biotech & drug discovery | SME | 1.1 | +51.6% | 14.4% |
| 208 | Helixmith Co., Ltd | Biotech & drug discovery | SME | 1.1 | -32.5% | 81.0% |
| 209 | KOREA PHARMA Co., Ltd. | Pharma & CDMO | SME | 1.1 | -22.6% | 2.2% |
| 210 | KOREAN DRUG CO., LTD. | Pharma & CDMO | SME | 1.1 | +11.0% | 3.5% |
| 211 | SEWOONMEDICAL CO,. LTD. | Medical devices | SME | 1.0 | +215.8% | 3.1% |
| 212 | KYUNG NAM PHARM.CO.,LTD. | Pharma & CDMO | SME | 1.0 | -3.8% | 3.1% |
| 213 | Autech Corporation | Medical devices | Mid-sized | 0.9 | +35.6% | 2.1% |
| 214 | EOFlow Co., Ltd. | Medical devices | SME | 0.8 | — | 373.2% |
| 215 | BITComputer | Medical AI | SME | 0.8 | +11.5% | 4.2% |
| 216 | L&K BIOMED CO., LTD. | Medical devices | SME | 0.8 | — | 10.3% |
| 217 | P&K Skin Research Center Co.,Ltd. | Biotech & drug discovery | SME | 0.8 | +2.5% | 6.2% |
| 218 | DongBang Medical Co., Ltd. | Medical devices | SME | 0.8 | -46.7% | 1.2% |
| 219 | RecensMedical, Inc. | Medical devices | SME | 0.8 | — | 28.5% |
| 220 | DaehanPharmaceutical | Pharma & CDMO | Mid-sized | 0.7 | -40.0% | 0.6% |
| 221 | ILSUNG IS CO., LTD. | Pharma & CDMO | SME | 0.7 | +30.5% | 2.0% |
| 222 | POONGJEON PHARMACY CO.,LTD. | Biotech & drug discovery | SME | 0.7 | -56.1% | 2.4% |
| 223 | WooGeneB&GCO.,Ltd | Pharma & CDMO | SME | 0.6 | +11.8% | 3.9% |
| 224 | DAIHAN SCIENTIFIC CO., Ltd | Healthcare infrastructure | SME | 0.6 | +18.9% | 1.5% |
| 225 | Alpha AI Co.,Ltd. | Medical devices | SME | 0.5 | +17.8% | 7.9% |
| 226 | DreamCIS INC. | Healthcare infrastructure | Mid-sized | 0.5 | -5.5% | 1.4% |
| 227 | HLB bioStep Co.,Ltd. | Biotech & drug discovery | SME | 0.5 | -23.2% | 1.7% |
| 228 | MOA Life Plus Co. Ltd. | Biotech & drug discovery | SME | 0.5 | +116.3% | 10.4% |
| 229 | MEZOO Co., Ltd. | Medical devices | SME | 0.5 | — | 4.9% |
| 230 | BIOBIJOU Co., Ltd. | Biotech & drug discovery | Mid-sized | 0.5 | +33.1% | 2.6% |
| 231 | LabGenomics. Co., Ltd. | Medical devices | SME | 0.5 | -55.3% | 1.4% |
| 232 | ChoA Pharmaceutical Co., LTD. | Pharma & CDMO | SME | 0.5 | -31.3% | 1.5% |
| 233 | SHINHUNG CO.,LTD | Medical devices | Mid-sized | 0.4 | -13.6% | 0.8% |
| 234 | UNION KOREA PHARM CO.,Ltd | Pharma & CDMO | SME | 0.4 | -17.5% | 3.2% |
| 235 | TELCON RF PHARMACEUTICAL. Inc. | Pharma & CDMO | SME | 0.4 | -5.0% | 0.9% |
| 236 | HIGH TECH PHARM CO.,LTD. | Pharma & CDMO | Mid-sized | 0.4 | +44.1% | 0.9% |
| 237 | BLUEMTEC CO., LTD. | Healthcare infrastructure | SME | 0.3 | -55.6% | 0.3% |
| 238 | HWAIL PHARM. CO., LTD | Pharma & CDMO | Mid-sized | 0.3 | — | 0.7% |
| 239 | SLSBio(Specialty Lab Solution Bio) Co., Ltd | Biotech & drug discovery | SME | 0.3 | +0.3% | 14.7% |
| 240 | GeneOne Life Science, Inc. | Pharma & CDMO | SME | 0.3 | -67.2% | 6.9% |
| 241 | HUMASIS CO., LTD. | Medical devices | SME | 0.3 | -29.2% | 1.8% |
| 242 | C&R Research Inc. | Healthcare infrastructure | SME | 0.3 | -75.2% | 1.0% |
| 243 | Daesung Microbiological Labs. Co. Ltd | Pharma & CDMO | SME | 0.3 | +36.2% | 2.7% |
| 244 | TDSPHARM Co., Ltd. | Pharma & CDMO | SME | 0.3 | -9.6% | 1.9% |
| 245 | Finemedix Co., Ltd. | Medical devices | SME | 0.3 | -19.9% | 4.3% |
| 246 | SCL Science Inc. | Medical devices | SME | 0.3 | — | 1.7% |
| 247 | IVIM Technology, Inc. | Pharma & CDMO | SME | 0.2 | -38.7% | 8.1% |
| 248 | GREEN LIFESCIENCE CO., LTD. | Pharma & CDMO | SME | 0.2 | -31.6% | 0.6% |
| 249 | CTC BIO, INC. | Pharma & CDMO | Mid-sized | 0.2 | -65.7% | 0.3% |
| 250 | RollingStone Co., Ltd. | Medical devices | SME | 0.2 | — | 0.3% |
| 251 | JMT CO.,Ltd. | Medical devices | SME | 0.1 | -32.9% | 0.1% |
| 252 | NATURECELL CO.,LTD. | Pharma & CDMO | SME | 0.1 | +38.2% | 0.6% |
| Rank | Company | Two-year R&D (KRW bn) | Approvals (n) | Korean trials (n) | Global trials (n) | Papers (n) | Patents (n) |
|---|---|---|---|---|---|---|---|
| 1 | Celltrion, Inc. | 902.4 | 20 | 18 | 13 | 36 | 46 |
| 2 | LigaChem Biosciences Inc. | 330.4 | 0 | 0 | 1 | 3 | 33 |
| 3 | Hanmi Pharm. Co., Ltd. | 438.8 | 23 | 9 | 12 | 72 | 114 |
| 4 | SK Bioscience Co.,Ltd | 262.0 | 0 | 2 | 1 | 16 | 40 |
| 5 | YUHAN CORPORATION | 511.2 | 31 | 9 | 26 | 27 | 55 |
| 6 | DAEWOONG PHARMA | 454.5 | 50 | 17 | 21 | 27 | 87 |
| 7 | Chong Kun Dang Pharmaceutical Corp. | 343.2 | 55 | 16 | 22 | 7 | 75 |
| 8 | SAMSUNG EPIS HOLDINGS Co., Ltd. | 419.2 | 13 | 0 | 2 | 22 | 10 |
| 9 | SK biopharmaceuticals Co., Ltd. | 335.6 | 0 | 0 | 1 | 3 | 29 |
| 10 | GC Biopharma Corp. | 346.6 | 36 | 5 | 3 | 14 | 27 |
| 11 | SAMSUNG BIOLOGICS CO.,LTD. | 309.0 | 0 | 0 | 0 | 3 | 21 |
| 12 | DONG-A ST CO.,LTD | 251.6 | 17 | 10 | 16 | 12 | 35 |
| 13 | ABL Bio Inc. | 167.5 | 0 | 1 | 1 | 8 | 20 |
| 14 | Kolon TissueGene, Inc. | 222.7 | 0 | 0 | 0 | 0 | 5 |
| 15 | MEDIPOSTCO.,LTD. | 129.3 | 0 | 0 | 0 | 5 | 1 |
| 16 | JW PHARMACEUTICAL | 191.2 | 18 | 12 | 10 | 0 | 51 |
| 17 | SD BIOSENSOR INC. | 166.0 | 66 | 0 | 0 | 4 | 45 |
| 18 | HK inno.N Corporation | 163.1 | 10 | 5 | 7 | 6 | 34 |
| 19 | Voronoi, Inc. | 76.5 | 0 | 0 | 3 | 4 | 45 |
| 20 | JEIL PHARMACEUTICAL CO.,LTD | 86.5 | 21 | 1 | 3 | 0 | 26 |
| 21 | Orum Therapeutics, Inc. | 85.7 | 0 | 0 | 0 | 0 | 12 |
| 22 | Boryung Corporation | 124.7 | 31 | 22 | 27 | 2 | 3 |
| 23 | SEEGENE, INC. | 135.6 | 4 | 0 | 0 | 68 | 115 |
| 24 | Aimed Bio Inc. | 38.7 | 0 | 0 | 0 | 0 | 14 |
| 25 | IL DONG PHARMACEUTICAL CO., LTD. | 46.0 | 31 | 2 | 1 | 0 | 55 |
| 26 | PharmaResearch Co., Ltd. | 57.4 | 7 | 0 | 2 | 1 | 10 |
| 27 | DAEWON PHARMACEUTICAL CO.,LTD | 101.1 | 37 | 18 | 7 | 3 | 11 |
| 28 | Medy-Tox Inc. | 86.6 | 1 | 0 | 0 | 12 | 13 |
| 29 | SAM CHUN DANG PHARM CO. LTD | 36.5 | 8 | 1 | 0 | 1 | 6 |
| 30 | HLB Co.,LTD. | 101.2 | 1 | 0 | 0 | 0 | 8 |
| 31 | HUONS CO., LTD. | 76.7 | 41 | 12 | 5 | 11 | 7 |
| 32 | GI Innovation Inc. | 68.7 | 0 | 1 | 1 | 5 | 27 |
| 33 | i-SENS, Inc. | 64.1 | 28 | 0 | 0 | 1 | 99 |
| 34 | OliX Pharmaceuticals, Inc. | 47.2 | 0 | 0 | 1 | 3 | 14 |
| 35 | KOREA UNITED PHARM INC | 67.1 | 9 | 11 | 4 | 4 | 15 |
| 36 | ILYANG PHARMACEUTICAL CO.,LTD | 57.9 | 32 | 7 | 8 | 4 | 2 |
| 37 | DongKookPharmaceuticalCo.,Ltd. | 60.6 | 61 | 3 | 1 | 3 | 8 |
| 38 | Qurient Co., Ltd. | 43.3 | 0 | 0 | 1 | 5 | 8 |
| 39 | SAMJIN PHARMACEUTICAL CO.,LTD | 71.0 | 26 | 2 | 0 | 2 | 18 |
| 40 | Mezzion Pharma Co., Ltd. | 37.7 | 0 | 1 | 0 | 0 | 1 |
| 41 | KYONGBO PHARMACEUTICAL CO., LTD. | 38.6 | 19 | 6 | 0 | 2 | 16 |
| 42 | OSCOTECInc. | 49.1 | 0 | 1 | 1 | 0 | 12 |
| 43 | BUKWANG PHARMACEUTICAL IND CO.,LTD | 54.6 | 5 | 0 | 0 | 0 | 0 |
| 44 | CLASSYS Inc. | 39.1 | 7 | 0 | 4 | 3 | 72 |
| 45 | Lunit Inc. | 72.4 | 1 | 0 | 1 | 64 | 60 |
| 46 | HANALL BIOPHARMA CO.,LTD | 69.0 | 3 | 1 | 2 | 0 | 9 |
| 47 | ST PHARM CO., LTD. | 45.8 | 0 | 0 | 0 | 8 | 43 |
| 48 | Rznomics Inc. | 26.1 | 0 | 1 | 2 | 2 | 7 |
| 49 | GC CELL CORPORATION | 51.7 | 0 | 1 | 3 | 4 | 20 |
| 50 | D&D Pharmatech Inc. | 48.3 | 0 | 0 | 0 | 3 | 9 |
| 51 | Genexine, Inc. | 49.1 | 0 | 1 | 2 | 7 | 14 |
| 52 | Inventage Lab Inc. | 37.7 | 0 | 0 | 1 | 4 | 52 |
| 53 | Vieworks Co., Ltd. | 52.5 | 8 | 0 | 0 | 1 | 75 |
| 54 | Curocell Inc. | 64.6 | 0 | 1 | 0 | 0 | 6 |
| 55 | DONGWHA PHARM.CO.,LTD | 49.9 | 30 | 0 | 0 | 1 | 7 |
| 56 | Boditech Med Inc. | 37.8 | 63 | 0 | 0 | 3 | 55 |
| 57 | BIONEERCORPORATION | 41.2 | 3 | 1 | 0 | 14 | 10 |
| 58 | HANDOK Inc. | 49.5 | 7 | 4 | 3 | 3 | 4 |
| 59 | SHINPOONG PHARMACEUTICAL CO.,LTD | 30.6 | 18 | 2 | 0 | 0 | 4 |
| 60 | Chabiotech Co.,Ltd. | 42.3 | 3 | 1 | 1 | 0 | 10 |
| 61 | Samyang Biopharm Corporation | — | — | — | — | — | — |
| 62 | OSANG HEALTHCARE CO.,LTD. | 41.0 | 31 | 0 | 0 | 0 | 11 |
| 63 | Aprogen, Inc | 110.7 | 0 | 0 | 0 | 0 | 2 |
| 64 | Huvitz Co., Ltd. | 42.6 | 3 | 0 | 0 | 3 | 84 |
| 65 | Peptron, Inc. | 29.2 | 1 | 0 | 0 | 2 | 8 |
| 66 | EuBiologics Co., Ltd. | 28.5 | 1 | 3 | 2 | 9 | 2 |
| 67 | Hana Pharm. Co., Ltd. | 29.3 | 20 | 5 | 0 | 1 | 4 |
| 68 | LivsMed Inc. | 24.9 | 16 | 0 | 0 | 2 | 102 |
| 69 | Hugel, Inc. | 30.0 | 1 | 0 | 2 | 2 | 11 |
| 70 | AHN-GOOK PHARMACEUTICAL Co., Ltd. | 40.2 | 11 | 5 | 6 | 0 | 4 |
| 71 | SillaJen, Inc. | 30.2 | 0 | 0 | 0 | 3 | 12 |
| 72 | Celltrion Pharm Inc. | 33.8 | 19 | 0 | 0 | 1 | 1 |
| 73 | BioNote, Inc. | 30.8 | 0 | 0 | 0 | 2 | 0 |
| 74 | DRTECH Corporation | 33.0 | 22 | 0 | 0 | 2 | 41 |
| 75 | ValueAddedTechnologyCo.,Ltd. | 28.8 | 9 | 0 | 0 | 0 | 35 |
| 76 | WHANIN PHARM CO.,LTD | 46.8 | 21 | 4 | 0 | 0 | 5 |
| 77 | CJ Bioscience | 40.9 | 0 | 0 | 0 | 20 | 2 |
| 78 | ISU Abxis Co., Ltd. | 29.7 | 0 | 1 | 0 | 3 | 4 |
| 79 | KANGSTEM BIOTECH CO., LTD. | 26.7 | 0 | 1 | 0 | 6 | 29 |
| 80 | QuadMedicine Inc. | 29.9 | 0 | 0 | 1 | 7 | 5 |
| 81 | S.Biomedics Co., Ltd. | 17.2 | 0 | 0 | 0 | 8 | 3 |
| 82 | MYUNGIN PHARM.CO., LTD | 28.6 | 15 | 2 | 0 | 0 | 0 |
| 83 | KOLON LIFE SCIENCE Inc. | 15.6 | 0 | 0 | 0 | 0 | 4 |
| 84 | AbClon Inc. | 27.8 | 0 | 0 | 0 | 1 | 14 |
| 85 | KWANGDONG PHARMACEUTICAL CO.,LTD | 30.4 | 12 | 0 | 0 | 4 | 13 |
| 86 | STCUBE | 24.3 | 0 | 2 | 2 | 1 | 0 |
| 87 | YUNGJIN PHARM. CO., LTD | 25.5 | 9 | 3 | 0 | 1 | 2 |
| 88 | SELVAS AI Inc. | 20.5 | 0 | 0 | 0 | 0 | 6 |
| 89 | CKD Bio Corp. | 26.7 | 2 | 0 | 0 | 2 | 19 |
| 90 | PharmGen Science, Inc. | 28.5 | 9 | 0 | 0 | 0 | 7 |
| 91 | KolmarBNH Co., Ltd | 24.3 | 0 | 0 | 0 | 1 | 26 |
| 92 | MedPacto, Inc. | 30.1 | 0 | 0 | 0 | 7 | 8 |
| 93 | GENORAY Co., LTD. | 23.0 | 7 | 0 | 0 | 0 | 3 |
| 94 | Genome&Company | 26.9 | 0 | 0 | 1 | 10 | 11 |
| 95 | meerecompanyIncorporated | 28.3 | 1 | 0 | 0 | 0 | 30 |
| 96 | KyungdongPharm | 24.6 | 23 | 2 | 0 | 0 | 1 |
| 97 | InBody Co., Ltd. | 24.1 | 6 | 0 | 0 | 1 | 16 |
| 98 | TiumBio Co., Ltd. | 21.3 | 0 | 0 | 0 | 1 | 4 |
| 99 | JETEMA Co.,Ltd. | 39.5 | 8 | 0 | 2 | 2 | 15 |
| 100 | Humedix Co., Ltd. | 18.6 | 7 | 1 | 1 | 1 | 2 |
| 101 | ENCell Co., Ltd. | 17.1 | 0 | 1 | 2 | 12 | 23 |
| 102 | Daehan Nupharm Co.,Ltd. | 16.8 | 11 | 3 | 0 | 0 | 5 |
| 103 | SUHEUNG CO.,LTD. | 17.3 | 22 | 0 | 0 | 3 | 13 |
| 104 | FutureChem Co., Ltd. | 15.1 | 0 | 2 | 0 | 4 | 2 |
| 105 | DAE HWA PHARM CO., LTD | 23.5 | 11 | 1 | 0 | 0 | 5 |
| 106 | WON TECH CO.,Ltd. | 14.9 | 23 | 0 | 0 | 3 | 15 |
| 107 | CUREXO, INC. | 19.9 | 1 | 0 | 0 | 1 | 70 |
| 108 | NEXTBIOMEDICAL Co., Ltd. | 14.8 | 4 | 0 | 0 | 1 | 5 |
| 109 | Shaperon Inc. | 19.7 | 0 | 1 | 1 | 11 | 17 |
| 110 | NEUROPHET Inc. | 12.7 | 6 | 0 | 2 | 30 | 9 |
| 111 | SEERS Co., Ltd. | 11.0 | 2 | 0 | 1 | 11 | 33 |
| 112 | G2GBIO, Inc. | 15.8 | 0 | 0 | 2 | 2 | 43 |
| 113 | CMG Pharmaceutical Co., Ltd. | 17.6 | 52 | 1 | 1 | 2 | 13 |
| 114 | Kukje Pharma Co., Ltd. | 11.2 | 10 | 0 | 2 | 0 | 1 |
| 115 | HLB PHARMACEUTICAL CO., LTD. | 11.4 | 11 | 1 | 0 | 0 | 4 |
| 116 | curacle co., ltd. | 20.4 | 0 | 0 | 1 | 4 | 3 |
| 117 | DENTIUM | 16.8 | 0 | 0 | 0 | 0 | 49 |
| 118 | Pharmicell Co.,Ltd. | 14.6 | 0 | 1 | 1 | 3 | 8 |
| 119 | Daebonglsco.,Ltd | 13.2 | 0 | 0 | 0 | 1 | 25 |
| 120 | Cellid Co., Ltd. | 32.8 | 0 | 1 | 0 | 10 | 29 |
| 121 | IMBiologics Corp. | 11.8 | 0 | 0 | 0 | 0 | 10 |
| 122 | INFINITT Healthcare Co., Ltd. | 17.4 | 3 | 0 | 1 | 1 | 3 |
| 123 | MEDIANA Co.,LTD | 9.5 | 2 | 0 | 0 | 3 | 15 |
| 124 | KOREA ARLICO PHARM CO.,LTD. | 10.1 | 30 | 3 | 1 | 0 | 3 |
| 125 | ORGANOIDSCIENCES LTD. | 11.0 | 0 | 0 | 0 | 13 | 18 |
| 126 | Sam-A Pharm. Co. Ltd | 11.6 | 2 | 1 | 0 | 0 | 4 |
| 127 | Synergy Innovation Co., Ltd. | — | — | — | — | — | — |
| 128 | ARIBIOLAB | 19.0 | 0 | 1 | 0 | 0 | 0 |
| 129 | CORESTEMCHEMON Inc. | 20.9 | 0 | 1 | 0 | 13 | 19 |
| 130 | Tego Science, Inc. | 8.5 | 1 | 1 | 2 | 1 | 2 |
| 131 | Bio Solution Co.,Ltd. | 14.3 | 0 | 0 | 0 | 0 | 11 |
| 132 | THERAGEN ETEX CO.,LTD. | 10.4 | 10 | 1 | 0 | 0 | 20 |
| 133 | JW LIFESCIENCE CORPORATION | 11.1 | 1 | 0 | 0 | 0 | 2 |
| 134 | Cellbion Co., Ltd | 12.3 | 2 | 1 | 1 | 2 | 3 |
| 135 | VUNO, Inc. | 11.2 | 14 | 0 | 1 | 22 | 44 |
| 136 | Noul Co., Ltd. | 18.8 | 0 | 0 | 0 | 5 | 18 |
| 137 | DEEPNOID Inc. | 12.3 | 3 | 0 | 0 | 14 | 24 |
| 138 | QuantaMatrix Incorporated | 10.0 | 0 | 0 | 0 | 2 | 3 |
| 139 | NIBEC CO., LTD. | 14.7 | 1 | 0 | 2 | 3 | 20 |
| 140 | Y-Biologics, Inc | 15.3 | 0 | 0 | 0 | 1 | 13 |
| 141 | L&C BIO Co., Ltd | 8.3 | 3 | 0 | 2 | 4 | 5 |
| 142 | SAMIL PHARMACEUTICAL CO.,LTD | 14.1 | 6 | 0 | 0 | 1 | 1 |
| 143 | KOMIPHARM INTERNATIONAL CO., LTD. | 7.1 | 0 | 0 | 0 | 6 | 2 |
| 144 | CG Invites Co., Ltd. | 15.9 | 0 | 0 | 0 | 1 | 6 |
| 145 | Micro Digital Co., Ltd. | 5.4 | 1 | 0 | 0 | 0 | 12 |
| 146 | HEM Pharma Inc. | 7.1 | 0 | 0 | 1 | 10 | 32 |
| 147 | CELL BIOTECH CO ., LTD | 9.0 | 0 | 1 | 0 | 10 | 12 |
| 148 | Amicogen, Inc. | 21.8 | 0 | 0 | 0 | 5 | 19 |
| 149 | SyntekaBio,Inc. | 5.2 | 0 | 0 | 0 | 2 | 27 |
| 150 | IT-CHEM Co., Ltd. | 11.1 | 0 | 0 | 0 | 0 | 2 |
| 151 | MYUNGMOON PHARM CO.,LTD | — | — | — | — | — | — |
| 152 | COSMO ROBOTICS CO., Ltd | 9.6 | 3 | 0 | 2 | 0 | 22 |
| 153 | METABIOMED.CO.,LTD | 10.0 | 10 | 0 | 0 | 0 | 3 |
| 154 | iNtRON Biotechnology, Inc. | 8.1 | 0 | 0 | 0 | 0 | 19 |
| 155 | Xcell Therapeutics Inc. | 8.4 | 0 | 0 | 0 | 0 | 6 |
| 156 | CAREGEN CO.,LTD. | 13.1 | 0 | 0 | 0 | 2 | 70 |
| 157 | SELVAS Healthcare, Inc. | 7.4 | 5 | 0 | 0 | 1 | 2 |
| 158 | SHINIL PHARMACEUTICAL CO., LTD. | 8.6 | 20 | 0 | 0 | 0 | 1 |
| 159 | Kolmar BioTech, Inc. | 11.4 | 0 | 0 | 0 | 0 | 1 |
| 160 | MITECH CO.,LTD. | 7.7 | 10 | 0 | 0 | 0 | 1 |
| 161 | 3billion Inc. | 7.7 | 0 | 0 | 0 | 64 | 13 |
| 162 | T&L Co., LTD. | 10.3 | 0 | 0 | 0 | 3 | 9 |
| 163 | Optipharm.CO.,LTD | 8.9 | 1 | 0 | 0 | 27 | 12 |
| 164 | ANTEROGEN CO., LTD. | 7.2 | 1 | 0 | 1 | 0 | 3 |
| 165 | REYON PHARMACEUTICAL CO., LTD | 7.7 | 6 | 2 | 0 | 0 | 1 |
| 166 | HLB PANAGENE Co., LTD. | 8.7 | 4 | 0 | 0 | 0 | 0 |
| 167 | Eutilex Co.,Ltd. | 24.1 | 0 | 0 | 0 | 1 | 8 |
| 168 | NanoenTek,Inc. | 8.1 | 2 | 0 | 0 | 0 | 4 |
| 169 | HLB Genex, Inc. | 17.4 | 0 | 0 | 0 | 0 | 9 |
| 170 | SAMSUNG PHARMACEUTICAL.CO.,Ltd. | 5.5 | 5 | 0 | 0 | 0 | 0 |
| 171 | ASTERASYS Co., Ltd. | 5.9 | 4 | 0 | 0 | 0 | 4 |
| 172 | BioPlus Co., Ltd | 6.3 | 1 | 0 | 0 | 0 | 2 |
| 173 | Corentec Co., Ltd. | 8.1 | 8 | 0 | 0 | 8 | 23 |
| 174 | Binex Co., Ltd. | 2.4 | 9 | 0 | 0 | 0 | 2 |
| 175 | DIO Corporation | 9.3 | 18 | 0 | 0 | 0 | 13 |
| 176 | KUKJEON Co.,Ltd | 6.6 | 0 | 0 | 0 | 1 | 6 |
| 177 | JW SHINYAK CORPORATION | 6.6 | 4 | 0 | 0 | 0 | 0 |
| 178 | CU MEDICAL SYSTEMS Inc. | 4.9 | 1 | 0 | 0 | 0 | 1 |
| 179 | PROTIA INC. | 5.3 | 6 | 0 | 0 | 0 | 4 |
| 180 | T&R Biofab Co., Ltd | 10.0 | 13 | 0 | 0 | 7 | 35 |
| 181 | DONGSUNG PHARMACEUTICAL CO.,LTD | 8.3 | 14 | 1 | 0 | 0 | 2 |
| 182 | Icure Pharmaceutical Incorporation | 6.1 | 7 | 0 | 0 | 0 | 19 |
| 183 | Gencurix Inc. | 8.7 | 1 | 0 | 0 | 4 | 4 |
| 184 | Aprogen Biologics Inc. | 23.7 | 18 | 5 | 0 | 0 | 0 |
| 185 | JPI Healthcare Co., Ltd. | 9.3 | 1 | 0 | 0 | 1 | 15 |
| 186 | Oncocross Co.,Ltd. | 6.3 | 0 | 0 | 0 | 8 | 7 |
| 187 | VIVOZON PHARMACEUTICAL CO., LTD. | 6.9 | 8 | 1 | 0 | 0 | 0 |
| 188 | Precision Biosensor Inc. | 6.2 | 20 | 0 | 0 | 2 | 7 |
| 189 | Coreline Soft Co., Ltd | 6.1 | 16 | 0 | 0 | 16 | 22 |
| 190 | Yuyu Pharma, Inc. | 8.2 | 15 | 0 | 0 | 1 | 2 |
| 191 | ENZYCHEM LIFESCIENCES CORPORATION | 8.0 | 0 | 1 | 0 | 3 | 4 |
| 192 | GC Medical Science Corporation | 6.6 | 10 | 0 | 0 | 0 | 1 |
| 193 | MEKICS Co., Ltd | 5.8 | 9 | 0 | 0 | 0 | 4 |
| 194 | DongKook Life Science Co., Ltd. | 4.8 | 11 | 0 | 0 | 0 | 0 |
| 195 | Acryl Inc. | 3.1 | 6 | 0 | 0 | 1 | 26 |
| 196 | Raphas Co., Ltd. | 4.0 | 0 | 0 | 0 | 11 | 18 |
| 197 | SINSIN PHARMACEUTICAL Co., LTD. | 5.3 | 24 | 2 | 0 | 0 | 4 |
| 198 | SEOUL PHARMA CO.,LTD | 5.4 | 8 | 1 | 0 | 0 | 0 |
| 199 | Plasmapp Co., Ltd. | 7.7 | 5 | 0 | 0 | 6 | 29 |
| 200 | CHOONG ANG VACCINE LABORATORY | 5.7 | 0 | 0 | 0 | 1 | 4 |
| 201 | JIN YANG PHARMACEUTICAL. CO., LTD | 4.3 | 13 | 6 | 0 | 0 | 2 |
| 202 | GFC Life Science Co., Ltd. | 3.6 | 2 | 0 | 0 | 6 | 46 |
| 203 | GENEMATRIX INC. | 6.1 | 2 | 1 | 0 | 1 | 4 |
| 204 | AMINOLOGICS CO.,LTD. | 4.1 | 0 | 0 | 0 | 0 | 3 |
| 205 | Daejung Chemicals & Metals Co., Ltd | — | — | — | — | — | — |
| 206 | Dynamic solution Co.,Ltd. | 6.8 | 2 | 0 | 0 | 0 | 7 |
| 207 | Pangen Biotech Inc. | 3.4 | 0 | 0 | 0 | 1 | 3 |
| 208 | Helixmith Co., Ltd | 11.6 | 0 | 0 | 0 | 3 | 13 |
| 209 | KOREA PHARMA Co., Ltd. | 4.8 | 14 | 2 | 0 | 1 | 1 |
| 210 | KOREAN DRUG CO., LTD. | 4.2 | 6 | 0 | 0 | 1 | 2 |
| 211 | SEWOONMEDICAL CO,. LTD. | 2.1 | 2 | 0 | 0 | 0 | 0 |
| 212 | KYUNG NAM PHARM.CO.,LTD. | 4.2 | 22 | 0 | 0 | 0 | 1 |
| 213 | Autech Corporation | 3.4 | 0 | 0 | 0 | 0 | 2 |
| 214 | EOFlow Co., Ltd. | 2.9 | 1 | 0 | 0 | 0 | 74 |
| 215 | BITComputer | — | — | — | — | — | — |
| 216 | L&K BIOMED CO., LTD. | 2.8 | 11 | 0 | 0 | 0 | 3 |
| 217 | P&K Skin Research Center Co.,Ltd. | 3.3 | 0 | 0 | 0 | 3 | 1 |
| 218 | DongBang Medical Co., Ltd. | 5.9 | 24 | 0 | 0 | 0 | 4 |
| 219 | RecensMedical, Inc. | 5.9 | 5 | 0 | 0 | 2 | 55 |
| 220 | DaehanPharmaceutical | 4.0 | 1 | 0 | 0 | 0 | 0 |
| 221 | ILSUNG IS CO., LTD. | 2.6 | 9 | 0 | 0 | 0 | 0 |
| 222 | POONGJEON PHARMACY CO.,LTD. | 9.5 | 0 | 0 | 0 | 0 | 5 |
| 223 | WooGeneB&GCO.,Ltd | 2.6 | 0 | 0 | 0 | 8 | 5 |
| 224 | DAIHAN SCIENTIFIC CO., Ltd | 2.2 | 2 | 0 | 0 | 0 | 0 |
| 225 | Alpha AI Co.,Ltd. | 2.0 | 2 | 0 | 0 | 0 | 6 |
| 226 | DreamCIS INC. | 2.4 | 17 | 1 | 0 | 1 | 2 |
| 227 | HLB bioStep Co.,Ltd. | 2.5 | 0 | 0 | 0 | 3 | 1 |
| 228 | MOA Life Plus Co. Ltd. | 1.4 | 0 | 0 | 0 | 1 | 3 |
| 229 | MEZOO Co., Ltd. | 1.6 | 2 | 0 | 1 | 9 | 5 |
| 230 | BIOBIJOU Co., Ltd. | 2.1 | 7 | 0 | 0 | 0 | 10 |
| 231 | LabGenomics. Co., Ltd. | 4.6 | 10 | 0 | 0 | 2 | 1 |
| 232 | ChoA Pharmaceutical Co., LTD. | 3.2 | 13 | 0 | 0 | 0 | 5 |
| 233 | SHINHUNG CO.,LTD | 1.6 | 27 | 0 | 0 | 0 | 0 |
| 234 | UNION KOREA PHARM CO.,Ltd | 2.2 | 6 | 0 | 0 | 0 | 1 |
| 235 | TELCON RF PHARMACEUTICAL. Inc. | 1.4 | 1 | 0 | 0 | 0 | 0 |
| 236 | HIGH TECH PHARM CO.,LTD. | 1.4 | 0 | 0 | 0 | 1 | 0 |
| 237 | BLUEMTEC CO., LTD. | — | — | — | — | — | — |
| 238 | HWAIL PHARM. CO., LTD | 1.5 | 0 | 0 | 0 | 0 | 3 |
| 239 | SLSBio(Specialty Lab Solution Bio) Co., Ltd | — | — | — | — | — | — |
| 240 | GeneOne Life Science, Inc. | 5.5 | 0 | 0 | 0 | 3 | 1 |
| 241 | HUMASIS CO., LTD. | 2.2 | 3 | 0 | 0 | 0 | 0 |
| 242 | C&R Research Inc. | 6.3 | 0 | 2 | 0 | 0 | 4 |
| 243 | Daesung Microbiological Labs. Co. Ltd | — | — | — | — | — | — |
| 244 | TDSPHARM Co., Ltd. | 1.3 | 2 | 0 | 0 | 0 | 1 |
| 245 | Finemedix Co., Ltd. | 1.1 | 12 | 0 | 0 | 0 | 14 |
| 246 | SCL Science Inc. | 4.1 | 3 | 0 | 0 | 1 | 15 |
| 247 | IVIM Technology, Inc. | 1.6 | 0 | 0 | 0 | 4 | 5 |
| 248 | GREEN LIFESCIENCE CO., LTD. | — | — | — | — | — | — |
| 249 | CTC BIO, INC. | 3.0 | 7 | 0 | 0 | 0 | 4 |
| 250 | RollingStone Co., Ltd. | 4.1 | 0 | 0 | 0 | 0 | 3 |
| 251 | JMT CO.,Ltd. | 0.6 | 6 | 0 | 0 | 0 | 3 |
| 252 | NATURECELL CO.,LTD. | 0.4 | 0 | 1 | 0 | 0 | 1 |
| · | Alteogen Inc. | 116.1 | 1 | 0 | 0 | 2 | 18 |
| · | Ensol Biosciences Inc. | 8.1 | 1 | 0 | 0 | 1 | 9 |
| · | Femtobiomed Inc. | 3.2 | 0 | 0 | 0 | 0 | 3 |
| · | Future Medicine Co., Ltd. | 6.7 | 0 | 0 | 0 | 19 | 9 |
| · | Hancom Lifecare Inc. | 4.6 | 0 | 0 | 0 | 0 | 10 |
| · | MEDYSSEY CO.,LTD | 2.0 | 4 | 0 | 0 | 0 | 4 |
| · | Moogene Medi Co., Ltd. | 2.8 | 0 | 1 | 0 | 2 | 12 |
| · | NovMetaPharma Co., Ltd. | 5.1 | 0 | 0 | 0 | 3 | 39 |
| · | ProGen, Co,, LTD. | 29.3 | 0 | 1 | 2 | 2 | 2 |
| · | UXN Co., Ltd. | 7.6 | 0 | 0 | 0 | 0 | 15 |
Two-year R&D and output cover 2024–2025 (patents: 2023–2024 filings). "·" rows have two-year values but no H1 2026 value and are included in two-year totals. "—" marks companies without both years, or with no disclosed output, which are not named (IV-5).